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ABSTRACT 
Introduced in dentistry more than 100 years ago, gutta-percha is the material of 
choice for root canal obturation, demonstrating minimal toxicity and tissue irritation. 
With the erupting incidences of latex allergies, there was a concern about the potential for 
immunological cross-reactivity between gutta-percha and natural rubber latex. Gutta-
percha is a rubber-like hydrocarbon derived from the sap of Payena and Palaquium gutta 
trees that are of the same botanical family as the Havea Brasiliensis trees that produce 
natural rubber latex. Gutta-percha is an isoprene polymer of a trans-arrangement, whose 
chemical composition is similar to the cis-polyisoprene of latex. One aim of this study 
was to test for this cross-reactivity. A total of twenty-two (22) female Dunkin-Hartley 
guinea pigs were divided into seven (7) groups. Two groups received latex implants 
subcutaneously, with one group getting a latex patch and the other getting a gutta-percha 
patch. Two groups received gutta-percha implants subcutaneously, with one group 
xm 
getting a latex patch and the other getting a gutta-percha patch. The remaining three 
groups were control groups. Two were negative controls, one receiving latex patches and 
the other receiving gutta-percha patches. The last group was the positive group receiving 
latex protein injected subcutaneously and latex paint on the skin of the animal. The 
implanted materials were left for fourteen ( 14) days before the patches were applied. The 
patches were placed for three (3) days before the animals were euthanised. Blood samples 
were drawn on days 1 and 14 (before placing the patches), day 14 six hours after placing 
the patches, and on dayl 5 and 16. After the animals were euthanised, tissue samples were 
obtained where the patches were applied and where the materials were implanted. H&E 
stained slides were prepared. The blood samples were analyzed by Western blot assay. 
The clinical, histological and immunological results indicated that there was no cross-
reactivity between latex and gutta-percha. No detectable allerginicty for gutta-percha was 
observed however inflammatory reaction in tissue around implanted latex and gutta-
percha was detected. It was concluded that the commercial gutta-percha tested did not 
contain the extractable proteins that can cross-react with latex. However if gutta-balata is 
added to the manufactured gutta-percha, caution should be considered when using this 
product to obturate root canals in latex-allergic patients. 
XIV 
INTRODUCTION 
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INTRODUCTION 
Archaeologists have found that latex has been used as early as 1600 BC, but it 
took until approximately 1900 AD before surgical gloves were commonly used. Apparent 
allergic reactions to natural rubber (NR) were documented in the medical literature in 
1927, and irritant delayed contact reactions were reported in 1933. It was not until the 
early 1980's that an immediate-type allergy provoked by NR products had been reported 
around the world. This was known as "Latex Allergy" which was first reported in 1979-
80 in Europe (Nutter , 1979; Forstrom , 1980), and in 1989 in North America (Slater, 1989; 
Taylor et al., 1989). This has been partially attributed to the increased use of rubber 
medical products recommended by the Center for Disease Control and Prevention for 
universal infection control. 
Although the incidence of latex allergy is an estimated 5% - 17% among health 
care workers (HCW), the incidence among others can reach an estimated 67% especially 
in children with spina bifida (SB) and other myelodysplasia cases. Other individuals who 
may experience latex allergy are patients with urogenital congenital abnormalities or 
history of multiple surgeries during early childhood. People with allergic reactions to 
fruits, plants and pollens may also show some allergic reaction to latex (Charous et al., 
1994). 
Latex 1s found in numerous products, thus the latex allergy phenomenon is 
becoming more prominent, and is causing adverse latex reactions that range from contact 
dermatitis (Type IV hypersensitivity) to life-threatening anaphylactic shock (Type I 
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hypersensitivity). Some of the dental materials that are currently in use, one of which is 
gutta-percha endodontic points, may contain NR. 
NR is derived from the latex of the rubber tree Hevea brasiliensis cultivated 
mainly in Malaysia, Indonesia and Thailand. Gutta-percha is derived from Paliquium 
gutta that is from the same botanical family as the rubber tree, and there lies the potential 
of cross-reactivity. The very close molecular structures of gutta-percha and NRL account 
for a number of similarities in their physical properties. The difference in their 
mechanical behavior is related to their different forms. Gutta-percha is a partially 
crystalline polymer as opposed to the amorphous form of NRL. Immunological cross 
reactivity between gutta-percha and NRL has not been demonstrated clearly. Several 
suspected cases were reported in the literature, but to date no study has conclusively 
demonstrated that gutta-percha is a causative agent of adverse allergic reactions in 
individuals with latex sensitivity. 
This study aims to shed a light on the composition and chemistry of the materials 
of concern; their similarities and differences; the mechanism of tissue response to the 
materials, and some case reports that were documented. The main objective of this study 
is to examine in vivo if there is any allerginicty to gutta-percha and if there is a cross-
reaction to gutta-percha in a latex sensitized individual. 
3 
LITERATURE REVIEW 
4 
LITERATURE REVIEW 
Latex 
Background of Latex: 
Over 200 species of plants produce rubber, but only Hevea Brasiliensis produces 
rubber in commercially significant quantities. Natural Rubber Latex (NRL) is the milky 
sap of the mature rubber tree, H Brasiliensis that is primarily cultivated in Malaysia, 
Indonesia and Thailand (Yungigner, 1995). Although natural rubber was discovered in 
Central and South America and in the Caribbean, the trees cannot be cultivated 
extensively in these locations. 
The rubber trees are tapped usually on alternative days to extract latex. Tapping 
begins once the tree reaches maturity (about seven years), and it involves cutting spiral 
grooves in the bark of the tree trunk periodically, then collecting the oozing sap. Since it 
quickly coagulates and forms ribbons or strands, latex are collected in cups containing 
ammonia that prevents auto-coagulation and bacterial contamination (Spina & Levine, 
1999). 
Ammonia disrupts the collected sap and the rubber particles resulting in a 2-phase 
product that is 30-40% solids. To prepare the liquid latex concentrate, the collected latex 
is centrifuged to remove part of the unwanted serum. This concentrates the rubber content 
for about 60% solids, resulting in ammoniated latex containing 1.6% ammonia by weight. 
This concentration can also be reached by creaming; a process that is controlled by 
adding calcium alginate (a salt derived from seaweed). Although ammonia effectively 
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stabilizes the latex, high levels may cause skin irritation. To overcome this problem, low 
ammonia levels with a concentration of 0.15-0.25% are used with combination of 
secondary preservatives such as sodium pentachlorophenate, tetramethylthiuram 
diphosphide and zinc oxide, to prevent coagulation and contamination. Additional 
chemicals such as accelerators (thiurams, zmc diethyldithiocarbamate, 
mercaptobenzothiazole) and antioxidants (phenylenediamine) are added for strength, 
stretch and durability (Themido & Brandao, 1984). 
Products containing natural rubber are made using two commonly manufacturing 
processes. About 10% of the collected rubber is used to manufacture dipped-products 
such as rubber gloves, catheters , adhesives, carpet backing and balloons. The remaining 
90% of the collected latex is used to manufacture Dry Natural Rubber (DNR). 
To manufacture dipped products, the NRL is centrifuged and a concentrated 
material is obtained. When ultracentrifuged, latex can be separated into 3 main fractions; 
a top rubber hydrocarbon particle phase, an ambient C-serum in which all latex particles 
are suspended, and a denser bottom fraction of non-rubber particles, particularly lutoid, 
which contains B-serum (Yip & Caciolo, 2002). 
Latex is made heat-stable and elastic by vulcanization (heating in the presence of 
sulfur). Sulfur atoms form cross-links between the loosely coiled polymeric chains of 
NRL causing elasticity of the chains. When they are stretched, the cross-links cause them 
to spring back when stress is released. 
To manufacture latex gloves, porcelain molds are coated with coagulating salts, 
then dipped in the already vulcanized latex compound and oven dried. After drying, the 
gloves are washed through leaching tanks to remove excess water-soluble proteins and 
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chemicals. The gloves are then lubricated with powder and pulled off the porcelain molds 
(Yip & Caciolo, 2002). The bulk of the proteins are removed when the latex is processed 
into its products. Only a small amount remains in the products as residual extractable 
proteins, the cause of allergic reactions in sensitized individuals. A survey of the 
extractable protein showed that levels could vary from as low as 20µg /g to 1 000µg/g 
(Yunginger et al., 1994). 
To manufacture Dry Natural Rubber (DNR) , NRL is coagulated, creped, 
crumbled, and washed extensively before being dried and compressed at temperatures 
more than 160°C, a temperature at which the proteins in the natural rubber are denatured 
(McKenna, 1997). In contrast to the wide range of extractable protein content found in 
NRL, the amounts of those protein fractions in dry rubber products were found to be 
extremely low. The Food and Drug administration (FDA) have noted that there are lower 
natural rubber proteins in products produced by DNR process. However, the FDA did not 
state that DNR does not cause allergic reactions in individuals sensitive to latex proteins. 
DNR products are vial stoppers, dry rubber plungers, intra-vascular injection ports and 
pneumatic tires (Food and Drug administration, 1997). 
NRL should not be confused with synthetic latex products such as water-based 
paints. These products use an emulsion of synthetic polymers or copolymers and do not 
cause any risk or reaction to latex-sensitive people. Synthetic rubbers are identical to 
natural rubbers in their physical properties. 
It was not until 1979, that Nutter explained an adverse reaction that developed to 
NR. Symptoms were consistent with an allergic reaction. Two types of allergies are 
associated with latex (Slater, 1994; Landwehr & Boguniewicz 1996). One is an 
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immediate Type I hypersensitivity that usually is a result of the extractable proteins that 
includes the enzymes in the natural rubber and their derivatives. Also the powders 
applied to the gloves act as a vehicle for a NRL aeroallergen that triggers Type I 
anaphylaxis allergic reactions to latex (Posch et al., 1998; Jaeger et al., 1992; Alenius et 
al., 1991 ). Chemicals added to latex such as the accelerators and antioxidants are 
responsible for Type IV allergic reaction ( contact dermatitis) (Themido & Brandao, 
1984; Conde-Salazar et al., 1993). 
Chemistry of Latex: 
Latex is a complex intracellular product of cells resulting from the synthesis of a 
polymer in a phospholipoprotein envelope and serum containing sugars, nucleic acids, 
lipids, minerals, and proteins. Latex is a polyterpene. Thus it consists of isoprene 
molecules linked into loosely twisted chains. The isoprene molecule is a hydrocarbon 
containing two double bonds. It is polymerized by the use of a special catalyst fanning a 
single large threadlike polyisoprene (C5H8) molecule (Marciano & Michailesco, 1989). 
CH3 
I 
CH2==C-CH==CH 2 
Isoprene formula ( C5H8) 
Polymerization of isoprene can result in different stereochemical structures of the 
polymer, depending on the number of double bonds involved in the polymerization 
8 
mechanism. If one double bond is involved in the polymerization, the resulting structure 
can either have the double bond between carbon atoms located in positions 1 and 2 
resulting in a 1-2 structure or between 3 and 4 resulting in a 3-4 structure. With both 
structures, when involved in polymerization mechanism , the resulting chain will have one 
double bond in each monomer unit. Depending on the positions of bonds adjacent to this 
double bond , polyisoprene occurs in two isomeric forms having the same molecular 
forms and different mode of atom arrangement. One of the forms is 1-4 cis-isomer where 
the single bond is located on the same side of the double bond (Marciano & Michailesco , 
1989). The monomer units along the backbone of the carbon chains in NRL are in a cis 
arrangement. The other form is 1-4 trans-isomer (gutta-percha) where the single bond is 
located on both sides of the double bond. Thus, polyisoprene can exist in four different 
stereochemical forms: 1-2, 3-4, 1-4 cis, and 1-4 trans. 
CH3 H 
\ I 
C==C 
I \ 
~~~~~H2C 
CH3 H 
\ I 
C==C 
I \ 
CH2~~~~~ 
Natural Rubb er ( cis-isomer) 
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Type I & IV Allergic Reactions 
An allergic reaction is one that is mediated by immunologic mechanism, thus an 
interaction of foreign molecule, or antigen, with host antibodies. 
Type I: 
It develops within minutes of exposure to the antigen and involves specific 
immunoglobulin (lg) E protein. Initial exposure results in cross-linking oflgE molecules 
by high affinity receptor allergen (Fe receptor) on the surface of mast cells and basophils. 
Thus, the cells now are sensitized. On second exposure, an antibody-antigen reaction at 
the cell surface causes mast cell and basophil degranulation. Membrane changes occur, 
along with ionic calcium influx and release of vasoactive amines such as histamine that 
produce acute inflammation. Other inflammatory mediators such as leukotriens, 
prostaglandin and kinins that are produced by arachidonic acid metabolism contribute to 
the delayed component of the reaction that usually develops hours after the original 
exposure to the antigen. (Raitt et al., 1998) 
Clinical picture: 
The anaphylaxis mediators result in immediate localized pruritus, stinging, with 
erythema, edema, and a wheal. A flare reaction occurs minutes later. After the initial 
reaction, conjunctivitis, generalized urticaria of the skin, dyspnea, palpitations , dizziness , 
sneezing and rhinitis occur. Systemic reactions include bronchospasm, respiratory 
distress, asthma hypotension, cardio-respiratory collapse and shock with angioedema 
affecting the tongue and oropharynx. Orbital and periorbital edema may also be observed. 
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The majority of deaths are due to the respiratory complications ( dysnea and laryngeal 
edema). (Roitt et al., 1998) 
Type IV: 
This is due to chronic exposure to chemicals that act as haptens to bind to proteins 
of the skin. It manifests within 24 to 48 hours after contact with the allergen. Langerhans 
cells process the antigen and present it to "T" cells in the local lymph nodes. On re-
challenge with the allergen, the sensitized "T" cell migrates to the skin and releases 
cytokines that attract macrophages to the site and activates them. The cells responsible 
are a subgroup of CD4+ TH cells. The macrophages produce tissue damage that may 
develop into a chronic granulomatous reaction if the antigen persists. The macrophages 
release TNF-a and lysosomal enzymes that damage the skin. Meanwhile, I-cytotoxic 
cells cause lysis and death of epidermis cells. The reaction is thus characterized by 
mononuclear cell infiltration with edema and microvesicles in the epidermis. An 
increased number of leucocytes are present in the dermis. (Roitt et al., 1998) 
Clinical picture: 
The clinical appearance of allergic contact dermatitis is similar to that of irritant 
contact dermatitis. Skin lesions appear as itchy, erythematous diffused eczema on the 
exposed surfaces. The reaction can later become generalized, and chronic exposure may 
lead to hyperkeratosis. Allergic contact dermatitis symptoms are pruritus, cracking of the 
skin such as fissuring and chapping, scales, crusts, scabs, papules and vesicles. (Roitt et 
al., 1998) 
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Diagnosis of latex allergy 
Definitive testing for latex allergy is completed either with in vivo or in vitro 
tests, where the in vivo tests are more sensitive and clinically more relevant. Currently, 
the most reliable test is the skin prick test. It has a sensitivity of 90-95% (kelly et al., 
1993). Note that skin prick testing can cause anaphylaxis. This has a reported incidence 
of 2% (Burton, 1997). 
The skin prick test: 
It involves introducing the allergen into the skin. An immediate wheal and flare 
up is an indication of positive reaction. When the allergen is introduced, the release of a 
preformed mediator increases vascular permeability causing edema and itching. (Roitt et 
al., 1998) 
The skin patch test: 
It involves placing a piece of latex glove in sterile saline for 24 hours to elute 
antigens from the latex into the solution. A drop of the solution is then placed on the 
patient's arm. The test result is interpreted in 20 minutes. A flare and wheal is a positive 
reaction. (Roitt et al., 1998) 
The most common in vitro serologic tests for serum level of latex-specific IgE are 
radioimmunoassay (RIA), the radioallergosorbent test (RAST), enzyme-linked 
immunosorbent assay (ELISA), and immunoblotting (Western Blot). The RAST has not 
proved to be an accurate indicator of latex allergy. In comparison with skin prick tests, 
the RAST has a sensitivity rate of only 53% (Turjamnaa et al., 1988; Kump et al., 1993). 
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Some of the false negative results may have been related to the patients having antigen-
specific IgG (Makinen-Kiljunen, 1992). NRL protein especially Hevein have been 
measured by ELISA which showed 100% specificity (Alenius, Kalkkinen, Yip et al., 
1996; Alenius, Kalkkinen, Reunala et al. 1996). 
Radioimmunoassay (RIA): 
) 
It utilizes a variety of techniques that use radiolabelled reagents to detect antigen 
or antibody. The principle involves competitive binding of radiolabelled antigen and 
unlabeled antigen to a high affinity antibody. The antigen is generally labeled with a 
gamma-emitting isotope such as 1251. The amount of ligand bound to the assay plate is 
proportional to the amount of test antibody. (Roitt et al., 1998) 
Radioallergosorbent Test (RAST): 
It is a specialized RIA used to detect antigen-specific IgE. Antigen is covalently 
coupled to cellulose discs, and specific IgE is detected using radiolabeled anti-IgE. (Roitt 
et al., 1998) 
Enzyme-linked Immunosorbent assay (ELISA): 
This test is used for detecting antibodies or antigens in ways analogous to RIA, 
but with the substitution of an enzyme for the radioactive isotope, which is detected using 
enzyme-labelled protein G (binds to IgG). The test has the advantage of stable reagents 
compared to RIA, but is less sensitive. (Roitt et al., 1998) 
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Immunoblotting (Western Blot): 
It is used to identify proteins that have been separated by gel electrophoresis and 
then transferred to a membrane (blot). The blot is incubated with radiolabelled or 
enzyme-labelled antibody that binds to antigens on the blot. The bound antibody can be 
detected by using a second layer radiolabelled anti-body, or enzyme-conjugated antibody. 
The principle is similar to RIA or ELISA. (Roitt et al., 1998) 
Case reports of latex allergy 
NRL products widely exist in modem society. Exposure to NRL starts at birth and 
continues through adulthood. There are an estimated 40,000 consumer products that 
contain NRL. These products include medical devices, dental materials, and household 
products (Spina & Levine, 1999). It is quite impossible to list all the products that contain 
latex, however, some are listed in Attachment 1 and 2. Latex exposure can occur through 
various routes, including the skin, mucous membranes, respiratory system, and vascular 
system. 
Although William S. Halstead at John Hopkins Hospital introduced surgical 
gloves made of rubber in 1890 (Spina & Levine, 1999); latex allergy has become a 
serious issue only over the last two decades. One important reason for that is the 
recognition that the allergy exists. Once the disease is identified, and diagnostic criteria 
have been formulated, it becomes easier for others to recognize similar cases. Another 
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factor that contributed to latex allergy becoming a serious issue in the 1980s was the 
increasing concern about AIDS and other transmissible infectious diseases. As the 
concern increased, the use of latex gloves and similar products dramatically increased. 
That in tum led to the policy of universal infection control precautions introduced by the 
Center of Disease Control (CDC), increasing the use of gloves, masks and other 
protective measures, most of which contain NRL (Spina & Levine, 1999). When the 
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demand for latex gloves increased, the quality of the gloves decreased which in tum led 
to leaching of more extractable protein. 
Attachment 1. Common household products that may contain latex 
Adhesives 
Athletic shoes 
Balloons 
Bandages 
Carpet backing 
Condoms 
Diaphragms 
Douche bulbs 
Elastic bands on clothing 
Elastic fiber in disposable diapers 
Erasers 
Eyedropper bulbs 
Halloween masks 
Hot water bulbs 
Household rubber gloves 
Infant pacifiers and feeding nipples 
Paints (some waterproofing paints) 
Rubber balls 
Rubber bands 
Rubber clothing ( e.g. raincoats) 
Rubber hand grips on racquets, bicycles, garden tools, etc. 
Rubber mats 
Rubber toys 
Tires 
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Attachment 2. Patient care supplies that may contain latex and cause latex allergy 
Dental supplies 
Bite block 
Nitrous oxide masks 
Orthodontic elastic 
Penros6 surgical drains 
Prophylaxis cups 
Resins 
Rubber Dam 
Rubber latex gloves 
Rubber stoppers on local anesthetic carpules 
General patients care supplies 
Band-Aids 
Blood pressure cuff and tubing 
Bulb syringes 
Chest tubes and drainage systems 
Electrode pads 
Enemas 
IV medication pumps 
Nasogastric tubes 
Patient identification bands 
Stethoscope tubing 
Tape 
Teeth protectors for intubation 
Temperature probes 
Urinary catheters 
Respiratory supplies 
Endotracheal tubes 
Facemasks 
Oropharyngeal and nasopharyngeal airways 
Pulse oximeter probes 
Suction catheter 
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Many latex allergy cases were reported over the years. The literature reported and 
documented hundreds of cases in different fields of medicine. The following mentioned 
cases just touch upon a few: 
A.F. Nutter reported the first clear immediate-type allergic reaction to NR in 1979 
! 
(Nutter, 1979). This report concerned a 34-year-old housewife with long standing atopic 
dermatitis, mainly involving her hands. When the patient attempted to wear a new pair of 
rubber gloves during a flare up of her hand eczema, she experienced intense itching 
within 5 minutes. Dr. Nutter confirmed the reactivity to components of the native NR by 
testing the patient with an extract of leaf from a Hevea brasiliensis tree. Due to the 
allergen that was present in the latex, this patient had an immediate reaction to the leaf 
extract. 
A case that was reported by Spaner in 1989 described a 34-year-old female 
operating room nurse who developed hand eczema to natural latex. On two occasions 
when she wore surgical gloves, symptoms developed. These symptoms were flushing, 
tachycardia, urticaria, angioedema, wheezing, and lightheadedness. Skin prick and patch 
tests were performed testing rubber additives (thiuram mix, mercaptobenzothiazole, 
phenylenediamine mix, and carbamate mix). These tests were negative, but when tests 
were performed to test NRL, the results were positive (Spaner et al., 1989). 
Tarlo et al conducted a survey of occupational asthma in workers in a surgical 
glove manufacturing plant (Talo et al., 1990). Eighty-one (81) workers underwent the 
survey, 6% had latex-related occupational asthma and 11 % had positive skin test 
responses to late::. 
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In a report in 1991, Ownby described six ( 6) severe anaph ylactic reactions during 
administration of barium enemas with one casualty. The cause of the anaphylactic 
reactions was the latex balloons found on the enema catheters. The cause of the reaction 
was confirmed by finding elevated serum tryptase levels (Ownby et al., 1991). Also in 
J 
1991, Sussman reported a series of patients who had allergic reactions to latex in a 
variety of medical settings including surgery and dental procedures (Sussman et al., 
1991). 
In another report, Vassallo described the case of a 16-year-old girl with known 
latex sensitivity. The patient developed an allergic reaction after the administration of a 
drug from a vial with latex stopper. It was reported that on two occasions the patient had 
a severe atopic reaction when examined with a latex glove. The Radioallergosorbent Test 
(RAST) for the latex antigen was positive, indicating that the allergic reaction the patient 
experienced was due to latex sensitivity (Vassallo et al., 1995). 
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Latex Allergen Cross-reactivity 
Individuals with certain food allergies may also have co-existing latex allergy 
(Lavaud et al., 1992), and allergic reaction to foods can also exist in latex sensitized 
individuals (Makinen-Kiljunen, 1994). This is known as the latex-food allergy syndrome. 
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Reports have described allergic reactions to an increasing number of fruits and vegetables 
in patients who are allergic to latex (Beezhold et al ., 1996). It appears that approximately 
50% of patients who are allergic to NRL have evidence of some food allergies (Turjanma 
et al., 1995). A study showed that lgE cross-reactivity existed between different latex and 
food allergens. This may be because many of the polypeptides found in rubber are also 
found in certain foods, especially fruits (Spina & Levine, 1999). The first reports of the 
latex food allergy syndrome were for the most common associates, banana (M'Raihi et 
al., 1991), chestnuts (Fernandez de Corres et al., 1993), kiwi, and avocado. Serologic 
sensitivity was also demonstrated to almond, walnut, hazelnut, apricot , pineapple, peach, 
nectarine, plum, cherry, melon , fig, grape, papaya, potatoes, tomato and celery (Hamann 
et al., 1998; Kurup et al., 1994). In an ADA health screening conducted by Hamann in 
1998, personnel who were susceptible to being latex sensitive answered positively to 
questions about food allergies. They were allergic to foods like banana, kiwi, milk, egg, 
avocado, com and cornstarch (Hamann et al., 1998). Symptoms of allergy to food are 
similar to those of latex allergy including anaphylactic shock, itching of the throat, 
asthma, and eczema. 
Axelsson et al. m 1985 and 1987 reported cases of occupational allergy to 
weeping fig tree:-> This involved two (2) persons working for a business that kept the fig 
tree as an ornamental plant in the office building (Axelsson et al., 1985). Another report 
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considered weeping figs as a source of indoor allergens. Thirteen (13) office workers 
with allergic symptoms demonstrated IgE antibodies to weeping fig extracts. Ten (10) of 
the thirteen (13) people had other food allergies (Axelsson, Johansson & Zetterstrom, 
1987). Allergens from weeping fig cross-reacted with allergens in NRL from Hevea and 
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with fig fruits (Brehler et al., 1998). 
In 1995, Gosgnach described the case of 63-year-old man admitted to the 
operating room for resection of abdominal aortic aneurysm. The man had no previous 
surgeries, but reported an allergy for shellfish. After placing the pulmonary artery 
catheter, a skin rash developed and systolic arterial blood pressure decreased from 120 to 
70 mmHg. The suspected diagnosis was an allergic reaction to any of the used materials 
that included iodine, lidocaine, and heparin in the catheter. The procedure was cancelled 
that day and an angiography was performed in which iodine was used. There was no 
adverse reaction excluding iodine to be the cause of the allergic reaction. On the day 
when the surgery was rescheduled, intravenous catheter was inserted. The patient 
developed skin rash and the systolic arterial pressure decreased. Allergy test was 
performed to test for allergies to lidocaine, iodine, fentanyl and latex. RAST were done to 
determine IgE. The results confirmed patients' sensitivity to latex (Gosgnach et al., 
1995). 
Santos described a 32-year-old woman who was thirty-nine (39) weeks pregnant 
and was seen for the first time in the labor room. The patient had a known allergy to 
orange juice. After a vaginal examination she experienced severe allergic reaction. Latex 
allergy was suspected and confirmed by a positive RAST (Santos et al., 1997). 
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Population at risk: 
With increased glove usage, there has been a parallel increase in the prevalence of 
latex allergy associated with several occupations and medical conditions. While only 1-
6% of the general population is allergic to latex, the prevalence in health care workers 
and others whose occupations involve exposure to rubber products such as employees in 
latex glove factories is around 10% (Arellano et al., 1992; Turjanmaa et al., 1996). 
Furthermore, young patients with disorders that require repeated surgical procedures such 
as children with spina bifida have been associated with an increased risk of latex allergy. 
Health Care workers (HCW) and employees o[latex products manufacturers: 
Numerous reports have suggested that between 8-17% of HCW may be allergic to 
NRL (Sussman et al., 1995; Tarlo et al., 1997). Persons employed in the manufacture of 
latex products have also been linked with a prevalence of 11 % of occupational allergies 
toward NRL (Tarlo et al., 1990). In a survey of US Army dentists' (Berky et al., 1992) 
13. 7% reported symptoms related to the use of latex gloves. The most common form of 
latex allergy among health care workers is Type IV hypersensitivity. However , in a 
recent study by the American Dental Association's annual health screening, 6.2% of the 
participants, mainly dentists, dental hygienists and dental assistants, showed positive 
signs of Type I hypersensitivity to latex proteins (Hamann et al., 1998). In fact, OSHA 
puts latex allergy in ninth place on its priority lists of hazards (Hamann et al., 1998). To 
date 16 fatalities related to latex anaphylaxis have been reported, none of which were 
related to dental treatment (Steelman , 1995). 
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Turjanmaa (1984) reported the first anaphylactic reaction to surgical gloves. The 
report described two female nurses with systemic allergic reactions. The first patient 
showed symptoms of generalized urticaria, bronchial obstruction and hypotension during 
delivery of her first child. Similar symptoms occurred four ( 4) years later with the same 
! 
patient during the delivery of her second child. The second patient had an anaphylactic 
reaction minutes after a surgical sterilization was done after her third pregnancy. Both 
patients when evaluated showed no sensitivity to anesthetic agents. Positive RAST and 
skin tests confirmed latex allergy. The IgE mediated nature of the skin test responses was 
confirmed with positive Prausnitz-Ktistner test result (Turjanmaa et al., 1984). 
From her European experience, Turjanmaa et al. (1995) explained that although 
HCW are the largest single group for NRL allergy, the majority of the NRL patients in 
their studies are non-health care workers. The same is probably true for the majority of 
the population. Axelsson et al. (1987) reported the first case of an anaphylactic reaction 
to latex in the dental profession. In their report, they described systemic reactions to 
rubber gloves in five (5) women, only one of whom was a HCW (Axelsson, Johanson & 
Wrangsjo, 1987) 
Children with Spina Bifida (SB): 
The other major risk group for latex allergy is children and adolescents with spina 
bifida cystica (Moneret-Vautrin et al., 1990) and multioperated pediatric patients (Gerber 
et al., 1989). They have increased incidence because of their frequent exposure to latex 
products from birth. Case reports confirm an alarmingly high rate of sensitization in 
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patients with spina bifida, thus increasing the likelihood of latex allergy. The frequency 
ranged from 32-51 % in SPT (skin prick test) screening (Kelly et al., 1993; Slater, 1994) 
and 34-47% in serologic IgE survey of such patients (Slater et al., 1991; Tosi et al., 1993; 
Pittman et al., 1995). They have IgE antibodies to NRL allergens mainly for proteins 
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with molecular weight 14 and 27 KDa (Alenius et al., 1993). 
Routes of exposure to latex allergen: 
The incidence of latex allergy has increased, but the pnmary route(s) of 
sensitization and the complete spectrum of latex proteins that result in allergic responses 
remain unclear. 
HCW and individuals employed in the manufacture of latex products are 
primarily exposed to latex proteins dermally as water-soluble latex proteins penetrate the 
skin (Hayes et al., 2000), and by inhalation, since latex proteins can aerosolize (Swanson 
et al., 1994), thus sensitizing HCW. Studies have also associated powdered-glove usage 
with increased allergic responses (Brehler et al., 1997) suggestive of inhalation 
sensitization. 
SB patients are additionally exposed subcutaneously. Up to 70% of SB patients 
have been diagnosed with IgE mediated latex allergy (Kelly et al., 1994; Cremer et al., 
1998). A positive correlation between the number of surgical procedures and latex allergy 
prevalence has been demonstrated within these patient populations (Chen et al., 1997; 
Porri et al., 1997). These studies support the possibility of mucosa! or subcutaneous 
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sensitization. Physiological fluids from surgical patients who come in contact with NRL 
products may elute additional latex proteins allowing for exposure to a unique set of 
proteins. 
Cutaneous Expo sure : 
Latex examination gloves have been shown to contain from 0.2-400µg proteins 
per glove (Zehr & Beezhold, 1995). Tests have shown that latex proteins were transferred 
onto the skin by donning the gloves (Beezhold et al., 1994). The implication for these 
data is that the skin is not only a route for NRL sensitization, but can be a major exposure 
route when the skin is not intact. The data further support the recommendation that only 
reduced-protein latex gloves should be used to avoid skin exposure and potential 
sensitization to NRL proteins. 
Hayes et al. (2000) demonstrated an increase in percutaneous penetration 
through abraded human skin. A strong correlation exists between the degree of skin 
abrasion and the amount of proteins penetrating, with less than 1 % penetrating through 
intact skin and up to 30% penetrating abraded skin. Protein penetrating the skin ranged 
from approximately 4 to 27 K.Da in size. These molecular weights correspond to several 
of the major latex allergens. Taylor and Praditsuwan (1996) correlated a clinical 
diagnosis oflatex protein allergy with atopy (77%) and pre-existing hand eczema (82%). 
Airborne Allergens: 
Cornstarch ( absorbable dusting powder-ADP) is presently used in manufacturing 
gloves to facilitate easy donning and to keep the gloves from sticking together. During 
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manufacture of the gloves, and before they are pulled off the porcelain molds, the gloves 
are dipped into a powder tank. They are then dried and removed from the molds. It is 
during the dipping process that the uptake of any unremoved residual extractable proteins 
from the gloves by the powder particles occurs. Thus, powder particles from poorly 
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processed gloves with high extractable protein content are likely to be loaded with 
undesirable proteins that could become aeroallergens when the powder particles became 
air-borne. The powder can bind and absorb NRL proteins from the gloves (Tomazic et 
al., 1994; Turjanmaa, 1994; Beezhold & Beck, 1992). 
Starch powders are polysaccharides comprised of glucose monomers joined in 
linear al, 4 linkages (amylose) and al, 4 linkages branched at al, 6 linkages 
(amylopectin) (Swanson & Ramalingam, 2002). Amylose molecules form helical 
structures that entrap molecules of the appropriate size. These complexes are referred to 
as inclusion compounds. Some studies reported that glove powder particles do absorb 
glove proteins, but in very small amount. The exact nature of the starch-protein 
interaction is unclear (Swanson & Ramalingam, 2002). 
When starch is hydrated , some of the starch molecules are drawn along the 
surface and form a membrane. This permits the soluble extractable protein to migrate 
within the wet latex film and become more leachable (Yungigner et al., 1994). Thus, with 
body sweat when wearing powdered gloves and similarly in people who are using oil-
based lotions, latex proteins become more soluble and accumulate between the latex 
gloves and the skin. The oil-based lotions may cause deterioration of the gloves, which 
leads to the latex proteins leaching out, causing allergies for latex-sensitized people 
(Swanson & Ramalingam, 2002). 
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It is rare to find quantifiable NR aeroallergen in homes, offices, schools and 
outdoors. Airborne NR allergens are commonly found in medical and dental office 
buildings, as well as in glove production facilities (Swanson et al., 1999). Swanson et al. 
(1994) quantified latex aero allergens in several areas of a medical center where powdered 
gloves )were used. Their evaluation showed that approximately 75% of powdered gloves 
had greater than 100µ,g of latex protein per gram of glove. Approximately 34% of the 
airborne particles collected were respirable. Based on human minute ventilation rates, a 
forty ( 40) hour work week could result in respiratory tract exposure of up to 1 Oµ,g of latex 
protein per week. 
Powder should not be a serious allergy issue when properly manufactured low-
protein powdered gloves are used. The uptake of protein by powder is reduced when the 
extractable protein content of the gloves is low (Tomazic et al., 1994). Nevertheless, 
more significant reduction in latex aeroallergens is reached by using powder-free latex 
gloves (Schwartz & Zurowski, 1993 ). In his studies, Yip et al. (1994; 1997) observed the 
relationship between the extractable protein and allerginicty. Their studies concluded that 
powdered latex gloves with low extractable protein level could have very low or 
negligible allerginicty or allergen content similar to that of low-protein powder-free 
gloves. In one study, a 10-KDa antigen could be demonstrated in glove powder, but when 
pure cornstarch glove powder was obtained from glove manufacturers, it did not cause 
positive tests in patients allergic to latex (Turjanmaa, Laurila et al., 1988). 
; 
According to the Food and Drug Administration, 65% of medical gloves used in 
the United States in 1997 were powdered latex gloves, and only 35% of them were 
powder-free latex gloves (Food and Drug administration, 1997). Due to the awareness of 
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latex protein allergy and the possibility that powder can become an aeroallergen, the 
percentage of powder-free gloves used has been reversed. Currently available powder-
free gloves are largely prepared by chlorination. The double bonds in the polyisoprene 
polymer in the NRL are very susceptible to the addition of chlorine. The chlorine added 
to the ~urface of the gloves stiffens and detackifies the rubber surface. The process of 
chlorination should be controlled carefully because over-chlorination will result in gloves 
having short shelf lives. The gloves will also become discolored and have a bad odor 
(Yip & Caciolo, 2002). A chlorination cycle of gloves involves pre-washing, exposure to 
a chlorine solution, neutralization, rinsing, and drying. Chlorinated products have 
generally reduced extractable protein levels. Cutaneous exposure to chlorinated 
cornstarch, used as dusting powder, produced no reaction in latex sensitive patients 
(Forstrom, 1980). 
Another type of powder-free gloves is the polymer-coated glove. The polymer 
replaces the powder as the donning lubricant. The bonding quality and the elasticity of 
the coating polymer determine durability of these gloves. Poor bonding or big differences 
in the elasticity between the NR and the coating will cause the coating to crack. The 
extractable proteins in these gloves are low (Yip & Caciolo, 2002). 
Most gloves that are labeled "hypoallergenic" contain latex proteins. It only refers 
to reduction in the chemical additives responsible for Type IV reaction, and not to the 
natural protein latex. The FDA believes that the term "hypoallergenic" is misleading and 
required that the label should be removed from materials or devices that contain natural 
rubber (Food and Drug administration, 1997). 
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Latex Proteins: 
It is the extractable proteins that include the enzymes in the natural rubber and 
their derivatives; along with the glove powder that are responsible for Type I anaphylaxis 
allergic reactions to latex (Posch et al., 1998; Jaeger et al., 1992; Alenius et al., 1991). 
Thus, dipped products are responsible for most immediate Type I reactions to NRL 
(Woods et al., 1997) as they have more extractable proteins and powder. The chemicals 
added to latex such as the accelerators and antioxidants are responsible for Type IV 
allergic reaction (contact dermatitis) (Themido & Brandao, 1984). In a study conducted 
as part of the ADA annual health screening, 6.2% of the participants, among whom were 
dental professionals, tested positive for Type I hypersensitivity to latex proteins (Hamann 
et al., 1998). Positive Prausnitz-Ktistner tests confirmed latex allergy as an IgE-mediated 
reaction (Kopman & Hannuksela, 1983; Turjanmaa et al., 1984). When skin-prick tests 
were performed on latex sensitive patients with 20-K.Da protein, positive results were 
obtained (Alenius et al., 1995). 
To better understand latex allergy, it is important to identify the major protein 
allergens in latex. Latex allergen appears to be a mixture of proteins in a molecular 
weight range from 4 to 67-K.Da (Jaeger et al., 1992). A tube-like network of specialized 
cells "lactifiers" are adjacent to the leaves of the Hevea brasiliensis tree The cytoplasm 
of these cells contain proteins that are involved in the biosynthesis of polyisoprene, 
coagulation of latex, and the plant's defense systems (Sussman et al., 2002). When 
ultracentrifuged, the latex separates into 3 main fractions: a top rubber phase, C-serum 
phase, and B-serum phase. Proteins comprise 1-1.5% of this latex system with about 27% 
of this being found in the rubber phase, 48% in the C-serum phase, and 25% in the B-
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serum phase. A study of these proteins revealed that there are two major surface-bound 
proteins of 14-KDa and 24-KDa in the rubber phase (Sussman et al., 2002). 
NRL contains more than 200 proteins (Slater, 1994). The bulk of the proteins are 
removed when the latex is processed into its products, and only a small fraction remains 
as residual extractable proteins. Thus, not all of the proteins that have been identified to be 
potential latex allergens survive the manufacturing process and remain as part of an 
extractable fraction of latex (Yunginger et al., 1996). Currently, the International 
Allergen Nomenclature Committee designates eleven (11) major and minor allergens: 
Hev b 1 Rubber elongation factor (REF): Czuppon identified it in 1993 as the 
first latex allergen (Czuppon et al., 1993). REF with its highly charged N-terminus, 
makes up 60% of the total protein found in latex. It is a 14.6-KDa protein that facilitates 
the elongation of the molecule to several isoprene subunits (Dennis et al., 1989; Dennis 
& Light, 1989;Light & Dennis, 1989). 
Hev b 3: another significant protein is a 22.3-KDa molecule. It has an important 
role in rubber synthesis because of its ability to synthesize long chain polyisoprene 
(Sussman et al., 2002). 
Hev b 5: is a 16-KDa protein that has been isolated from ammoniated latex, from 
heat-treated latex, and from glove extracts. Even after autoclaving, this acidic protein 
retains its allerginicty. Hev b 5 stimulates histamine release from basophils of patients 
sensitive to latex (Akasawa et al., 1996). 
Hev b 6.01: is a 20-KDa protein (Prohevein) (Alenius et al., 1995). It is processed 
to produce 2 allergenic fragments, the 4.7-KDa N-terminal hevein (Hev b 6.02), and the 
14-KDa C-terminal hevein (Hev b 6.03). Hevein is a cysteine and glycine-rich acidic 
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protein and is one of the major latex proteins. It is a chitin-binding protein believed to be 
involved in the coagulation of latex (Archer, 1960). 
Hev b 7: is a 42.9-KDa protein that is a cytosolic protein with esterase activity 
(Sowka et al., 1998). It is an inhibitor of rubber biosynthesis. 
Other minor proteins include Hev b 2 (35.1-KDa), Hev b 4 (50-57-KDa), Hev b 8 
(13.9-KDa), Hev b 9 (47.7-KDa), Hev b 10 (22.9-KDa), and Hev b 11 (33-KDa). Other 
allergens are also pres~nt in NRL such as Hevamine, a 25.9-KDa basic protein from the 
lutoids of NRL (Terwisscha et al., 1994). It exhibits chitinase and lysozome activity 
(Jekel et al., 1991). 
There appears to be a selective reactivity to certain proteins. Although the reasons 
for this are unclear, it is hypothesized to be due to different routes of exposure. REF 
Hevb 1(14-KDa), Hevb 3(22-27 KDa) and Hevb 7(43 KDa) are recognized more 
frequently by IgE from SB patients (Wagner et al ., 2001). Meanwhile, Hevb2 (35-36 
KDa), Hevb 4 (100-110 KDa), and Hevb 6.01, 6.02, and 6.03 (20-KDa, 5 KDa, and 14 
KDa respectively) are recognized more in HCW. They are freely soluble proteins to 
which a higher percentage of allergic HCW develop antibodies (Alenius et al., 1993; 
Hamilton & Adkinson, 1996; Posch et al., 1998; Yip et al., 2000). The molecular weights 
alone cannot be relied upon to identify specific latex proteins (Hevb 1, Hevb 6.03, and 
Hevb 8 have similar molecular weights). The different latex-specific IgE profiles 
observed in these studies following distinct sensitization routes is consistent with the 
hypothesis that the route of sensitization contributes to the varied specific antibody 
production among latex allergic patients (i.e. HCW and SB patients) (Woolhiser et al., 
2000). 
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In patients with food or plant allergies, plant protein has a sequence 
homology that could explain the cross reactivity to a variety of foods. Hevb 1 was found 
to contain protein sequence homology that cross-reacts with papain from papaya (Chen et 
al., 1996). Hevb 5 has sequence homology with protein from kiwi causing the cross-
reactivity with kiwi (Beezhold et al., 1999). Recent studies suggest that Hevb 6 is 
responsible for the ~ross reactivity with fruits. (Posch et al., 1999; Chen et al., 1998). 
Hev b 7 has structural homology to potato phospholipase (patatin), which is responsible 
for the cross-reaction with potato. Few latex allergic patients react to Hev b 8 suggesting 
that it is not responsible for extensive cross-reactivity (Yip et al., 2000). 
31 
Gutta-Percha 
Background of Gutta-percha: 
Gutta-percha is a plastic, rubber-like hydrocarbon derived from the latex of 
Payena and Palaquium gutta trees in Malaysia and South Asia and from the Balata tree 
in South America. Both are of same botanical family as the rubber tree (H. brasiliensis). 
Gutta-percha is a nqturally occurring trans-polyisoprene that is extracted from the leaves 
of these trees. The name gutta-percha is derived from the Malaysian word "getah", gum 
and "percha", the name of the tree. Gutta-percha consists essentially of "gutta", a 
hydrocarbon in a complex mixture with resinous substances that are probably oxidation 
products of gutta itself. Manufacturers sometimes add gutta-balata, another naturally 
occurring trans-polyisoprene, to produce commercially existing gutta-percha endodontic 
points. Gutta-balata is extracted from the Mimusops globsa tree (Costa et al., 2001). 
Mimusops globsa tree is from the same botanical family as H. brasiliensis and Palaquium 
gutta. 
Gutta-percha formulations have been used as endodontic filling material for more 
than 100 years, and whatever the method used (thermomechanical, lateral condensation), 
it is usually considered the best material for root canal obturation (Schilder, 1967; Marlin 
et al., 1981 ). Although regarded as an inferior temporary filling material by modem 
standards, it is widely accepted as the material of choice for the majority of endodontic 
procedures (Weine, 1982). '), 
References to the use of gutta-percha for root canal obturation before the 20th 
century were few. Gutta-percha was used to manufacture corks, insulators, electrical 
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cables, surgical instruments and golf balls. Prior to using gutta-percha, gold was used as 
the root canal filling material. In 184 7 Hill developed the first gutta-percha root canal 
filling material known as "Hill's stop". In 1883 Perry claimed to use gold wire wrapped 
with softened gutta-percha. In 1887 the S. S. White Company began manufacturing gutta-
percha points. In 1893 Rollins introduced a new type of gutta-percha with added 
vermilion. Callahan in 1914 added rosins to the gutta-percha, which helped in softening 
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it. Over the past 80 years several attempts took place to improve the nature of the gutta-
percha. (Gutmann & Witherspoon, 1998) 
To manufacture endodontic gutta-percha points, raw gutta-percha is isolated from 
the mature tree and ground to a fine pulp. The pulp is mixed with water, heated to 75°C 
to release the gutta-percha threads, and then cooled to 45°C. The gutta-percha flocculates, 
producing a yellow gutta that contains 60% polyisoprene and 40% contaminants (resin, 
protein, dirt and water). The yellow gutta is mixed with cold gasoline at below 0°C. The 
gasoline treatment not only flocculates the gutta-percha trans-polyisoprene, but it 
dissolves the resins and is believed to denature any residual gutta-percha proteins. The 
gutta threads are then redissolved in warm gasoline at 75°C and the dirt is allowed to 
precipitate. The residual greenish-yellow solution is bleached and filtered to remove any 
remaining residues. The product is then steam distilled to remove the gasoline, then 
modified with fillers to its final _~ommercial formulation (Dean, 1932; Friedman et al., 
1975; Marciano et al., 1993). 
At room temperature, gutta-percha is 60% crystalline and the remainder is 
amorphous in nature. According to Dean (1932) and Bunn (1942), there are two 
crystalline forms of gutta-percha: a and /J -forms. Although no difference exists in 
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mechanical properties between the two forms, gutta-percha undergoes crystalline phase 
changes at specific points during heating and cooling. The transformation temperatures of 
dental gutta-percha compounds are 42-49°C for the {3 to a and 53-59°C for a to 
amorphous transition (Schilder et al. 1974). Rapid cooling of an amorphous melt gutta-
percha results in crystallization of the f3 -form which occurs as the predominant form in 
most commercially available gutta-percha, while slow cooling of liquid gutta-percha 
results in the more brittle naturally occurring a -form (Oliet & Sorin, 1977). Although 
techniques of performing endodontic treatment involving heating of gutta-percha in the 
root canal, cause reversible physical changes, no apparent change in the chemical 
composition takes place (Cohen et al., 1992). 
Information concerning the nature and sources of the base materials used in 
processing dental gutta-percha are proprietary secrets. Thus, most investigations of the 
complex composition of gutta-percha used in dentistry are neither uniform nor 
comparable. From the Material Safety Data Sheet (MSDS) of gutta-percha, it states that 
the common synonym is transpolyisoprene, latex rubber, and isoprene rubber. The 
formula that appears on the MSDS sheet is C5H8 containing gutta-percha, zinc oxide, 
barium sulphate and coloring agents with no information about the amount or the 
percentage of each ingredient. It is however known that gutta-percha root canal filling 
r 
material is composed of: 20% gutta-percha, 66% zinc oxide filler, 11 % heavy metal 
(Barium sulfate), and 3% plasticizer (waxes, resins and coloring agents) (Friedman et al., 
1975). 
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The appearance of the gutta-percha points under SEM is "jelly bean" shaped 
particles of inorganic material interspersed between amorphous masses of organic resins 
(Oliet & Sorin, 1977). 
Chemistry of Gutta-percha: 
Gutta-percha is a high molecular weight isoprene polymer (C5H8). Polymerization 
of isoprene can result in different stereochemical structures of the polymer. Depending on 
the positions of bonds adjacent to the double bond, polyisoprene occurs in two isomeric 
forms having the same molecular forms and different modes of atom arrangement. The 
first is 1-4 cis-isomer form (NRL) where the single bond is located on the same side of 
the double bond. The other form is 1-4 trans-isomer- (gutta-percha) (Bunn , 1942; 
Goodman et al. , 1974) where the single bond is located on both sides of the double bond 
(Marciano & Michailesco , 1989). The monomer units along the backbone of the carbon 
chains in gutta-percha are in a trans arrangement. The trans configuration of gutta-
percha, where the isoprene molecules are bonded, is linear and crystallizes easily , hence 
the physical characteristic of being hard and brittle at room temperature (/3 form of gutta-
percha). The cis form of NRL crystallizes with difficulty giving it physical characteristics 
·~ 
of being elastic. 
~~~~~ H2C H CH3 CHr~~~~ 
\ I \ I 
C==C C==C 
I \ I \ 
H 
Gutta-percha (trans-ionomer) 
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Inflammatory Reaction to Gutta-percha 
Several investigators (Kawahara et al., 1968; Spangberg, 1969; Wolfson & 
Seltzer, 1975) who examined gutta-percha toxicity indicated that it is the least irritating 
root canal filling material. According to Wolfson & Seltzer (1975), gutta-percha is a non-
toxic, innocuous filling material and the small amounts of plasticizers, age resisters, 
coloring agents and other additive do not play a major role in influencing the quality of 
gutta-percha cones ~ 
In their study in 1990, Leonardo et al showed that different brands of gutta -percha 
showed different levels of inflammation. That was consistent with observations made by 
Holland et al. (1978). Both studies reported that the inflammatory response was intense, 
becoming moderate then mild after 21, 60 ~nd 120 days. The development of a fibrous 
capsule with a dense proliferation of fibroblasts was observed. Spangberg (1969) and 
Wolfson & Seltzer (1975) were also in agreement with those demonstrated these results. 
All of the materials used to seal root canals irritate the periradicular tissue. The 
argument seems to be not whether this happens, but rather to what degree and for how 
long it is irritated. The observed decrease in severity of inflammation to gutta-percha 
suggests it is an inert material (Spangberg, 1969; Wolfson & Seltzer, 1975; Holland et 
al., 1978; Leona ~do et al., 1990). The absence of inflammatory reaction after 12 months 
in a study done by Friend (1968) suggests that once the root canal sealer is set, they are 
inert. 
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Case reports of gutta-percha and Latex 
Two case-reports in the literature discussed adverse reactions to gutta-percha 
observed in patients with type I NRL allergy who had endodontic treatment (Boxer et al., 
1994; Gazelius et al., 1986). The reports have suggested that gutta-percha may release 
proteins that induce reactions in latex-allergic individuals. 
The first case mentioned (Gazelius et al. , 1986) described a latex-allergic female 
nurse who experienced pulsating pain accompanied by tachycardia, dysnea , and fever 
two (2) hours after endodontic obturation of her mandibular left second molar. Although 
these symptoms were not characteristic to those of latex allergy, they were still attributed 
to the gutta-percha obturation because the pain persisted until the gutta-percha was 
removed three (3) months later. 
A more recent report (Boxer et al., 1994) described the case of a 35-year-old 
hygienist with a history of NRL allergy who experienced immediate discomfort after 
gutta-percha was used as the root canal filling material in her maxillary molar. Symptoms 
of allergic reaction , such as lip and gingival swelling, a throbbing sensation around the 
tooth, and diffuse urticaria were noticed. The patient consulted an endodontist four ( 4) 
weeks later as the pain persisted. Radiographs of the tooth revealed gutta-percha 
overextended ~beyond the root apex. After removal of gutta-percha and placement of 
silver point and calcium hydroxide, the patient experienced immediate relief of oral 
discomfort and the remission of the urticaria! lesions within few hours (Boxer et al., 
1994). 
However , in both cases, their conclusions were based on assumptions that the 
similar botanical background between gutta-percha and NRL implied cross-reactivity. It 
37 
was also assumed that the endodontic gutta-percha points contained significant amounts 
of gutta-percha protein; and that other endodontic materials used in the procedures were 
not allergic. These reports, however, have not proven cross-reactivity between Hevea 
latex and gutta-percha. 
To date, no study has conclusively demonstrated that gutta-percha is a causative 
agent of adverse allergic reactions. Moreover, in other case reports , no adverse effects 
were observed when gutta-percha was used in patients with type I NRL allergy (Knowles 
et al., 1998; Kleier & Shibilski, 1999). 
Knowles reported a case involving a 33-year-old female with a history of severe 
rubber latex allergy. As a result of her allergy, she carries 2 epi-pens of 0.3 mg of 
epinephrine, injectable Benadryl, and a Proventil inhaler with her at all times. Her 
physician recommended premedication with prednisone, Benadryl and Claritin before the 
treatment appointment. After finishing and obturating the root canal with gutta-percha, 
the patient came in contact with a rubber handgrip device on a dental instrument and 
immediately experienced another anaphylactic reaction, the circumstances , conditions 
and symptoms, however, remain highly suspicious of a rubber latex/gutta-percha allergy 
(Knowles et al., 1998). 
Kleier and Shibilski reported a case about a 42-year-old female who 
presented for a root canal treatment and experienced a Type I hypersensitivity reaction to 
latex. The patient was sent to an immunologist who performed a RAST and skin test. The 
only material she reacted to was the latex-containing rubber dam. The immunologist 
advised the patient that gutta-percha and other non-latex dental materials could be safely 
used. This case report demonstrates that there is no automatic cross-reactivity with gutta-
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percha in patients who are allergic to latex. Theoretically, if the gutta-percha could be 
completely confined within the root canal space, no antigen would be present to react 
with the body's immune system (Kleier & Shibilski, 1999). 
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ANIMAL MODEL 
GUINEA PIGS: 
Historically , gumea pigs have been used to investigate systemic and dermal 
anaphylaxis and recent investigation by Hayes et al. (2000) have shown guinea pig skin 
to be a good surrogate for human skin with respect to penetration of latex proteins. An 
abraded skin model may more closely represent the skin condition of individuals at risk 
for latex allergy. The physiological characteristics of the guinea pig skin are similar to 
that of man . This is the reason guinea pigs are often used as models for various allergic 
reactions and other areas of investigations such as that of wounds and bums. 
Guinea pigs are capable of making antibodies to latex protein components that 
mediate dermal and systemic anaphylaxis , paralleling the spectrum of clinical and 
laboratory findings of humans with immediate-Type I latex hypersensitivity. Aamir et al. 
(1996) demonstrated that guinea -pigs immunized subcutaneously with non-ammoniated 
latex or components of NRL mixed with Freund's complete adjuvant developed latex-
specific antibodies capable of mediating dermal and systemic responses . The major shock 
organ for the guinea pig is the lung, which makes it a good model for evaluating 
pulmonary responses; however , the major reaginic antibody for the guinea pig is IgG 1, in 
contrast to IgE for the human. The Dunkin-Hartley strain in particular is more sensitive 
and quicker in reacting to allergen. They develop immediate and systemic responses that 
are very similar to those of humans (Heller & Regal, 1991). 
Time-course and dose-response studies have shown that multiple subcutaneous 
administration of as little as 0.19µg of non-ammoniated latex protein (NAL) elicited IgE 
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production in 5 weeks. Animals (BALB/c mice) exposed subcutaneously, intratracheally ; 
or topically to 12.5µ,g of non-ammoniated latex demonstrated IgE production within 2, 3 
and 5 weeks, respectively (Woolhiser et al., 2000). 
According to a study by Wrangsjo et al. (1994), 14g of latex glove material in 
50ml saline was used to make a latex allergen extract to be used in adult humans (~60 
Kg). 
Studies conducted by Hayes et al. (2000) showed that coetaneous exposure to 
100µ,g of latex proteins five (5) days per week for three (3) months induced an IgG1 
response in 35% of the animals exposed in the study. Woolhiser et al. (2000) exposed 
BALB/c mice to 50µ,g of latex protein through abraded skin causing them to develop 
elevated levels of IgE in twenty-three (23) days. 
ADJUVANT: 
Adjuvant is a compound that enhances the immune response when administered 
with antigen, thus producing higher antibody titers. Since the implant discs are 
considered haptens , an adjuvant is needed. A hapten is an artificial antigen that has been 
used to examine immune response. Haptens bind to antibodies but cannot by themselves 
elicit an antibody response. Compared to using the antigen alone, using antigen plus an 
adjuvant generally permits use of much smaller quantity of the antigen and greatly 
enhances the antigen titer. 
Freund's Complete Adjuvant (FCA) has been used for many years to enhance 
immunologic responses to antigens. Although FCA is a very effective adjuvant for 
production of antibodies, there have been problems and hazards associated with its use 
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and a number of new adjuvants became available to use in laboratory animals in the past 
few years (Broderson, 1989; Claassen et al., 1992; Kleinman et al., 1993). At the site of 
use, FCA causes a chronic inflammatory response that may be severe and painful for the 
animal. The inflammatory response may result in formation of chronic granulomas and/or 
ulcerating tissue necrosis. FCA is also a potential hazard for laboratory personnel. 
Accidental self-inoculation can result in tuberculin sensitization followed by chronic 
local inflammation that responds poorly to antibiotic treatment (Chapel & August 1976). 
TiterMax is an oil/surfactant-based adjuvant prepared as a water-in-oil emulsion 
m a manner similar to that used for FCA. Dr. Robert Hunter developed it in 1991 
specifically as a replacement for FCA (Hunter et al., 1991). When compared to FCA, 
Titer Max can be used in smaller quantities, which minimizes the inflammatory reaction 
at the application site (Bennett et al., 1992). 
Aluminum salt Adjuvant (Alum) is commercially available as AL(OHh It can be 
used to absorb proteins in a ratio of 50-200g protein/mg aluminum hydroxide. Adsorption 
of protein is dependent on the pl (Isoelectric pH) of the protein and the pH of the 
medium. A protein with a lower pl adsorbs to the positively charged aluminum ion more 
strongly than protein with a higher pl. Aluminum salts are generally weaker adjuvants 
than emulsion adjuvants; however, because of their generally mild inflammatory 
reactions, they are safer to use. The mineral adjuvant causes nonspecific activation of 
macrophages and complement activation. In their study (Aamir et al., 1996) to test guinea 
pig as a model of hypersensitivity to allergenic fractions of NRL, the researchers used 
Alum adjuvant incorporated with the non-ammoniated latex. 
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OBJECTIVES OF STUDY 
43 
OBJECTIVES OF STUDY 
Is it safe to use gutta-percha points as an endodontic filling material in patients 
with Type I allergic reaction? According to the hypothesis, the similar botanical 
background between gutta-percha and NRL and their similar chemical makeup may lead 
to cross-reactions with both materials. The objective of this study was to investigate the 
potential cross-reactivity between gutta-percha and NRL by studying the histological and 
immunological changes and to investigate the allerginicty of gutta-percha. 
The experiments aimed at this objective were designed to: 
1. Sensitize guinea pigs to latex. 
2. Determine whether or not gutta-percha will sensitize the guinea pigs. 
3. Clinically examine the guinea pigs for any signs of allergy. 
4. Examine the histology slides for any changes. 
5. Analyze the Western blot assay for any reaction. 
6. Examine any cross-reaction between both NRL and gutta-percha. 
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MATERIALS AND METHODS 
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MATERIALS AND METHODS 
Materials: 
Material Manufacturer Area 
Dunkin-Hartley guinea-pigs Charles River Laboratories Wilmington, MA 
Gutta-percha Obtura Co. Fenton, MO 
~ 
Powder free latex exam gloves BSC Medical Supplies, Inc. Union City, CA 
Non-ammoniated latex protein Guthrie Research Institute Syre, PA 
Vinyl gloves Baldur System Corp. Hayward, CA 
Paper tie-on mask Henry Schein Inc. Melville, NY 
Titer Max adjuvant CytRx Corp. Norcross, GA 
Alum (aluminum salt) adjuvant Accurate Chemical and West bury, NY 
Scientific Corp. 
Vinyl Transpore surgical tape 3M Healthcare St. Paul , MN 
½ inch 
Uni-punch Premier Medical Products King Of Prussia, PA 
Waxed weighing paper Fisher Scientific Co. Pittsburgh, PA 
f 
Pyrex® 60x 15mm glass petri Coming Inc. Coming, NY 
culture dishes 
Metal scalpel handles Henry Schein Inc. Melville, NY 
Surgical blades #15 Henry Schein Inc. Melville , NY 
Ketamine (Ketaset) Fort Dodge Animal Health Forte Dodge , IA 
Xylocaine (Xyla J ect) Phoenix Pharmaceutical Inc. St. Joseph, MO 
Saline AmTech Group, Phoenix - St. Joseph, MO 
Pharmaceutical Inc. 
70% Isopropyl alcohol American Fare Troy, MI 
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Perfrktum *Micromate Popper & Sons, Inc. New Hyde Park, NY 
Interchangeable 5ml glass 
syringes- LuerLock 
Perfrktum *RustlessSteel Syringe Popper & Sons, Inc. New Hyde Park, NY 
23 guage 5/8" needles- LuerLock 
Perfrktum*RustlessSteel Syringe Popper & Sons, Inc. New Hyde Park , NY 
22 guage 1" needles- LuerLock 
HotStart 100 Storage and Molecular Bio Products Inc. San Diego, CA 
Reaction tubes 
4.0 silk suture material with Ethicon Inc. Somerville, NJ 
attached P-3 needle 
Disp,osable 50ml centrifuge tubes Fisher scientific Co. Pittsburgh , PA 
10% buffered formalin solution American BioAnalytical Natick , MA 
Equipment: 
Material Manufacturer Area 
Tare-XE series scale, model 300 Denver Instrument company. Denver, CO 
Coming stirrer/ hotplate Coming Inc. Coming, NY 
Touch'n Heat, model 5002-200V Analytic Endodontics Redmond, WA 
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Guinea pigs: 
For approval to perform research using animals, an application for use of animals 
m research and education was submitted to the Institutional Animal Care and Use 
Committee (IACUC) at Boston University School of Medicine. It covered questions 
about the nature of the research and the need for the use of animals in this particular 
study. It also covered information about where the animals will be housed and the 
location of the experiment itself. The questionnaire included inquiries about the usage of 
any radioactive agents , infectious agents, carcinogens, mutagens and other biohazards. 
The application covered questions about the species of the animals to be used and the 
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rationale behind selecting that species. The number of animals used was also asked along 
with how that number calculated and whether or not the animals would be used in more 
than one project. The application included a summary of the research protocol, discussion 
of the scientific goals, rationale, and methodology by which the study will be carried out. 
It also inquired about the welfare of the animals and any pain they might be subjected to 
and if there was any alternatives to the usage of animals in the study or procedures 
involving pain and distress. The degree of pain was questioned and the plan for handling 
that in terms of administering pain medications. The application also touched up on the 
anesthesia, materials to be used in the experiment with the preoperative preparation, and 
postoperative care. The inquiries included the surgical procedure to be conducted, any 
survival from that and any stress the animals might suffer. The method of euthanasia was 
checked especially if drugs were to be used , along with the needed dosages and methods 
of administration. 
Sur,gery room preparations and bedding preparation 
The guinea pigs were maintained under conditions specified within the Guide for 
the Care and Use of Laboratory Animals (NIH , 1996). They were kept in a latex free 
environment so that any positive reaction would be a result of the materials used and not 
due to any other external factors. The animals' housing was in stainless steel suspended 
caging, with no-contact bedding. The cages were modified rabbit cages in an 
environment regulated at approximately 72°F and 60% relative humidity with light/dark 
cycles at twelve (12) hour intervals. Feeding /water containers were glass bowls with flat 
bottoms to avoid tipping. The containers were changed and cleaned daily. Food consisted 
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of TekLab Guinea Pig Chow and distilled water, both given ad libitum. Both food and 
water were supplied by the IACUC. The other cubicles in the housing room complied 
with this "latex free" environment. The staff was strictly instructed to use latex free 
products when handling the guinea pigs. This included using vinyl gloves, paper tie-on 
masks, stainless steel scoops, stainless steel carts, and cardboard / paper liners. It was 
recommended that all animal care should be provided in the morning before caring for 
the animals in the other cubicles. A reminder notice (Attachment 3) was posted both at 
the door of the animal housing room and at the cubicle. The surgery room was organized 
in the same manner as the housing room, with the same reminder notice posted at its 
door. The researcher also used disposable latex free gowns, paper tie-on masks, glass 
protective goggles, and vinyl gloves. Any plastic item that needed to be used, such as the 
electric hair clipper, was wrapped with transpore surgical tape. 
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Boston University Medical Center 
Center for Advanced Biomedical Research 
Laboratory Animal Science Center 
700 Albany Street 
Room W-707 
Boston, MA 02118 
Telephone: (617)638-4086 
Fax: (617)638-4055 
"LATEX-FREE" 
RESEARCH ACTIVITIES 
DO NOT USE: 
LATEX HAND GLOVES 
MOLDEX FACE MASK 
PLASTIC TRASH CAN LINERS 
PLASTIC FEED AND/OR BEDDING SCOOPS 
RUBBER/PLASTIC FEED BARREL 
PLASTIC STORAGE SHELF 
PLASTIC-BACK BLUE CHUCKS 
PLASTIC SHARPS-CONTAINER 
LATEX-FREE GUINEAPIGSTUDY 
AUTHORISED USE: 
VINYLGLOVES 
PAPER, TIE-ON MASK 
FIBER DRUM WITH NO LINER 
STAINLESS STEEL SCOOPS 
FIBER DRUM 
STAINLESS STEEL CART 
CARDBOARD/PAPER LINER 
METAL SHARPS-CONTAINER 
(researcher provides) 
1. ALL ANIMAL CARE PERFORMED FIRST BEFORE OTHER 2 CUBICLES 
2. COMPLETE ALL ANIMAL CARE IN A.M. BEFORE BEGINNING OTHER CUBICLE 
ACTIVITIES 
3. STAINLESS STEEL ANIMAL CAGING 
4. CERAMIC FEED AND WATER BOWLS 
5. ANIMAL MANIPULATIONS PERFORMED IN W730 PROCEDURE ROOM 
6. SAME "LATEX-FREE" REQUIREMENTS IN W730 PROCEDURE ROOM 
REMINDER: 
NO PLASTIC, RUBBER, LATEX MATERIALS ARE TO BE BROUGHT INTO 
THIS ANIMAL ROOM 
Attachment 3. Notice posted on surgery room and housing room of guinea pigs 
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Latex and Latex protein 
Dr. Donald Beezhold at the Guthrie Research Institute (Syre, PA) generously 
provided the latex protein needed for this study. Four ( 4) vials containing non-
ammoniated latex protein (3mg/vial) for a total of 12mg were sent to the Biomaterials 
Laboratory at Boston University, School of Dental Medicine. The lyophilized protein was 
stored at 4 °C until used. It was reconstituted in a carbonate buffer at pH 9. The protein 
has a pl (lsoelectric pH) of 4-5. 
Preparation of gutta-percha, and latex implants and patches: 
To prepare the gutta-percha implants, the gutta-percha was placed between two 
warm glass slabs to soften it. The glass slabs were warmed using corning stirrer/hotplate. 
The warm glass slabs were squeezed against one another to form sheets with an even 
thickness of gutta-percha. Using disposable 8mm biopsy punches, the gutta-percha was 
cut in disc shaped portions. Because the puncher handle was made of plastic, it was 
wrapped with vinyl tape before preparing the discs. 
Fig 1. The gutta-percha pellets squeezed between warm glass slabs for implant 
preparation 
51 
Using a laboratory balance, 0.14g of gutta-percha was weighed on waxed 
weighing paper to be implanted in a 600g guinea pig. The gutta-percha implants were 
kept in 60x15mm Pyrex® glass petri culture dishes until used. For consistency, latex discs 
were prepared the same size and weight as gutta-percha. The latex discs were made from 
latex gloves. The latex implants were also kept in glass petri dishes until used. 
Fig 2. 0. l 4g.of gutta-percha implant material is weighed 
Fig 3. Similarly prepared gutta-percha and latex implant materials kept in glass petri dish 
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The gutta-percha patches were prepared in uniform thickness sheets as the discs 
were. Using a metal #15 blade, the gutta-percha was cut in 1cm x 1cm squares. Holes 
were placed in the four corners of the square using a Touch'n Heat instrument to 
facilitate suturing to the guinea pigs' skin. Latex squares 1 cm x 1 cm were also prepared. 
Both latex and gutta-percha patches were kept in separate glass petri dishes. 
Fig 4. Gutta-percha patch prepared and kept in petri dish until used 
--J When preparing the discs and the patches, gutta-percha and latex were prepared 
separately and at different times to minimize any airborne allergens. They were prepared 
whil~ wearing vinyl gloves and paper tie-on masks. The environment was kept latex 
free/controlled at all times. 
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Methods 
Experiment Day Scheduled task 
Day#l • Anesthesia ) 
• 1st blood draw before placing the implants [bl 1] 
• Placement of implants in groups A, B, C and D 
• Injection of protein in group G 
Day #2-6 Monitor the guinea pigs 
Day#7 Suture removal from groups A, B, C and D 
Day #8-13 Monitor the guinea pigs 
Day #14 • Anesthesia and 2nd blood draw pnor to placing the 
patches /protein paint [bl 2] 
V"' • Placement of the patches in groups A, B, C, D, E and F 
• Painting protein in group G 
Six (6) hours later Anesthesia, 3rd blood draw [bl 3] 
Day #15 (24 hours later) Anesthesia, 4th blood draw [bl 4] 
Day #16 (48 hours later) Anesthesia, 5th and final blood draw, and Euthanasia [bl 5] 
Table 1. A timetable for the experiment design 
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After the approval of the Institutional Animal Care and Use Committee (IACUC), 
twenty-two (22) female Dunkin-Hartley guinea pigs 600g each (11 weeks old) were 
purchased from Charles River Laboratories. In the younger animals it was hard to find 
the Anterior Vena Cava to obtain sufficient blood draw. The guinea pigs were 
quarantined for one (1) week at the Animal Service Center, Boston University Campus. 
Each cage housed three (3) compatible animals, with maximum six (6) cage units. They 
were marked using pierced ear tags. The total duration of the experiment was sixteen (16) 
days. 
Experiment Day # 1 
The guinea pigs were brought to the surgery room, and were anaesthetized to 
draw blood. Each guinea pig was lifted with a firm, gentle-pressure grasp around the 
thorax. It was not suspended for a long time to avoid any stress and rapid support was 
provided to the animal. The hind legs were grasped with the other hand and held gently in 
anJextended position that enables manipulating the animal. 
The guinea pigs were anaesthetized with 2.5ml/Kg of the anaesthetic mixture 
consisting of Ketamine hydrochloride (100 mg/ml) and xylocaine (20 mg/ml) at ratio of 
7:3, respectively. Adding 0.7ml Ketamine and 0.3ml xylocaine to 4ml saline produced a 
5ml of the anaesthetic mixture [ all anesthesia containers were obtained from IACUC]. 
The hair at the site of injection was clipped using an electric razor whose plastic handle 
housing was wrapped with transpore vinyl tape and the site was swabbed with 70% 
isopropyl alcohol. Using a 5ml glass syringe, and a 23 gauge 5/8" needle, the anaesthetic 
mixture was injected in the gluteal muscle after aspiration to avoid injecting in a blood 
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vessel. The injection of 1.5ml, which anaesthetized the 600g guinea pig was administered 
with a steady fluid motion to avoid tissue trauma. 
Fig 5. The anaesthetic mixture administered in the gluteal muscle of the guinea 
pig, demonstrating the way to hold and handle the animal 
Once the animal was anaesthetized, blood was withdrawn utilizing the Anterior 
Vena Cava. The area was prepared by putting the animal on its back and clipping the hair 
at the sternum area and swabbing with alcohol. A 5ml glass syringe with a 22 gauge l" 
needle was inserted at the junction of the upper most position of the sternum and first rib 
on the right side at a 30° angle while aspirating the needle. The needle was directed 
toward the midline at a depth no greater than 10mm. Once blood appeared in the syringe, 
the plunger of the syringe was drawn back and up to 0.5cc of blood was collected (bl 1). 
Upon completion, good homeostasis was insured before moving on to the next step. The 
collected blood was placed in 0.5mm vials containing 0.013ml ofEDTA (K 3) [obtained 
from IACUC], to prevent coagulation. The blood vials were marked and kept at 4°C until 
further use. 
56 
Fig 6. Blood draw from the anterior Vena Cava at the junction of the sternum and the first 
rib. 
While the guinea pigs were still anaesthetized, they were turned on their ventral 
surface. The back of their neck where the implants were to be placed was shaved with the 
razor then swabbed with alcohol. A 1 cm horizontal incision was made using # 15 blade 
attached to a metal handle. A subcutaneous pocket was prepared to receive the implant 
material. 
V" 
Fig 7. Incision at the back of the neck and the gutta-percha implants placed in place. 
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The discs were implanted as follows: 
Group A received latex implants. 
Group B received latex implants. 
Group C received gutta-percha implants. 
Group D received gutta-percha implants. 
( 
A few drops of TiterMax adjuvant were added at the incision site. The incision was 
sutured with 3-4 interrupted sutures using 4.0 black silk suture material attached to a 
cutting P-3 needle. The incision and the sutures were covered by transpore vinyl tape. 
Groups E and F did not receive any implants because they were control groups. 
Group G is the positive control group receiving latex protein aliquots. The protein was 
injected subcutaneously after grasping the nape of the neck of the guinea pig with the 
thumb and forefinger. The area was swabbed with alcohol and the injection was inserted 
at the base of the skin folded between the two fingers. No blood was to be aspirated and 
the injection was administered with a steady unbroken motion. A few drops of Alum 
ajljuvant were added at to the aliquots. 
The guinea pigs were kept warm until they recovered from the anesthesia, almost 
one hour after the procedure was completed. The animals were the moved back to their 
cages. After surgery, their activities and movements were monitored, as well as was their 
ability to eat. 
The guinea pigs were monitored daily. They ate regularly, and were playful and 
active. There were no signs of distress. The implants and protein injections were left for 
14 days before placement of the patches. Tables 2 and 3 show experiment groups. 
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Latex implant Gutta-percha implant No implant ..., Injectable Latex 
Groups A B C D E F G 
+ + + + + + + 
Patches 
Gutta-percha Latex patch Gutta-percha Latex patch Gutta-percha Latex patch Latex protein 
Patch patch patch paint 
Table 2. Experiment Groups 
Groups Implant Patch # of Guinea pigs 
Blood Draw Blood Draw Blood Draw* 
A 1 Latex 1 Gutta-percha 3 4 
B 1 Latex 1 Latex 3 3 
C 1 Gutta-percha 1 Gutta-percha 3 3 
D 1 Gutta-percha 1 Latex 3 4 
E 1 None None Gutta-percha 3 3 
F 1 None None Latex 3 3 
G 1 Injectable latex 1 Latex paint 3 2 
Table 3. Experiment Design 
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Experiment Day #7: 
The animals from groups A, B, C and D were held with a firm and gentle grip 
during suture removal. Only topical anesthetic was used for this procedure. 
Experiment Day #14: 
In the surgery room, the guinea pigs were anaesthetized. 0.5cc of blood was 
drawn (bl 2), and then the animals were placed on their ventral surface. At an area on 
their backs away from the implant site hair was removed with the electric clippers, 
followed by a shave with a razor blade. The area was swabbed with isopropyl alcohol; the 
skin was slightly abraded using # 15 blade. The patches were placed on the skin and 
secured with four interrupted sutures, one on each comer of the square patches. The 
patches were then secured in place by a covering of vinyl transpore tape. 
Fig 8. Gutta-percha patch sutured in place over the shaved and slightly abraded skin on 
the back of the guinea pig 
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Group A received gutta-percha patches. (Latex /gutta-percha) 
Group B received latex patches. (Latex /latex) 
Group C received gutta-percha patches. (Gutta-percha /gutta-percha) 
Group D received latex patches. (Gutta-percha /latex) 
Group E received gutta-percha patches. (None /gutta-percha) 
Group F received latex patches. (None/latex) 
Group G: In this group, an area on the back of the animals away from the subcutaneous 
injections was clipped and shaved to the skin. That shaved area was painted with 100µ,1 (2 
drops) of the latex aliquots. (Injectable latex protein/protein paint) 
The animals were monitored closely for any immediate allergic reaction. After the 
animals recovered from the anesthesia , they were observed for any changes on the skin or 
any irritation and behavioral changes. Six (6) hours after placing the patches and protein 
paint, the guinea pigs of all seven (7) groups were anaesthetized and another blood draw 
was performed [bl 3]. 
Experiment Day #15: 
Twenty four (24) hours later, a second blood draw was done [bl 4]. 
Experiment Day #16: 
Forty eight ( 48) hours after placing the patches and protein paint, a third and final 
blood draw was obtained. The animals were prepared for euthanasia [bl 5]. 
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Euthanasia: 
According to the 1993 report of the AVMA (American veterinary medical 
association), the recommended method of euthanasia to rodents, guinea pigs and small 
animals was inhalant anaesthetic, CO, and CO2. Using CO2 is a moderately rapid method 
and relatively easy to perform in a closed clear plastic container. It causes direct 
depression of cerebral cortex, sub-cortical structures and vital centers with depression of 
the heart muscle leading to hypoxia. The animals were placed in the clear plastic 
container one animal at a time. The gas pressures were maintained at 95% CO2 and 5% 
0 2 until the animal was euthanised. 
The animal skin of all seven (7) groups where the patch was placed was sectioned 
out surgically and placed in disposable sterile 50ml centrifuge tubes with 20ml of 10% 
buffered formalin solution. Sections of subcutaneous tissue containing the implants with 
surrounding connective tissue were obtained from groups A, B, C, D and the injection 
site of group G. The tissue sections were placed in formalin. The remains of the animals 
were disposed of according to the instructions and regulations of the IA CUC. 
Fig 9. Subcutaneous tissue extracted surgically after euthanasia. The tissue shows 
embedded latex implant 
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Histology preparation: 
The tissue sections were preserved in formalin in a biohazard incubator until they 
were sent to a pathology lab for histology slide preparation. The sections were sent to the 
Skin Pathology Laboratory at Boston University School of Medicine. The request was for 
paraffin embedded sections, the slides to be un-coated and stained with Haematoxylin 
and Eosin (H & E). The sections were to be prepared at an approximate thickness of 
seven (7)µ. The slides were kept in room temperature until examined. 
Blood preparation: 
The collected blood was kept at 4°C until it was packed in dry ice and sent to Dr. 
Donald Beezhold at Guthrie Foundation (Syre, PA.) where a Western blot was done 
using an antibody sandwich technique. The protocol followed for the W estem blot was as 
follows: 
"Protein preparations were separated by SDS-PAGE on 15% gels, and transferred to 
nitrocellulose (0.1 um, Schleicher and Schuell). The membrane was blocked with 3% 
non-fat diary milk for I hr, and reacted overnight with 1/100 dilution of guinea pig sera. 
After washing, the blots were reacted for 1 hr with a 1/15,00 dilution in 0.2% dry milk of 
alkaline-phosphatase (AP) labeled anti-guinea pig lgG (whole molecule), Sigma A5062. 
The IgE reactive latex proteins are visualized using the AP substrate nitroblue tetrazolium 
and bromo-chloro-indolyl phosphate (NBT/BCIP). Color was allowed to develop for 30 
min." 
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RESULTS 
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Results 
This study involved the clinical evaluation of twenty-two (22) female Dunkin-
Hartley guinea pigs' skin. The study also involved histological evaluation of 
subcutaneous tissue and skin sections stained with Haematoxylin and Eosin (H & E) in 
order to determine if there was any sensitization to gutta-percha material, and if there was 
any cross-reactivity to latex. 
Of the twenty-two guinea pigs, four (4) of which were assigned to group A and 
four (4) to group D. Each of groups, B, C, E and F were assigned three (3) guinea pigs. 
The last two (2) guinea pigs were for group G. 
The study also involved evaluation of blood samples utilizing W estem blot assay. 
Clinical Examination: 
In all groups, none of the guinea pigs showed stress or any type of adverse 
reaction to the implanted material or to the subcutaneously injected allergen for the 
duration of the experiment. There was no apparent reaction within minutes or for up to 
six ( 6) hours after placing the patches. When checking the animals twenty-four (24) and 
forty-eight ( 48) hours after placing the patches, there was still no signs of any skin 
itchiness, redness or other signs of skin inflammation or allergy observed. 
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Group A {Latex implant/gutta-percha patch): 
Fig 10. Normal clinical skin at patch site of group A. Note: red areas are sites of suturing. 
Group B {Latex implant/latex patch): 
Fig 11. Clinical picture of group B showing normal skin at patch site. 
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Group C (Gutta-percha implant/gutta-percha patch): 
Fig 12. Clinical picture of group Cat patch site appears normal. 
Group D (Gutta-percha implant/latex patch): 
Fig 13. Normal looking clinical picture of group D at patch site. 
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Group E (Gutta-percha patch): (Control group) 
Fig 14. Clinical picture of group E shows normal intact skin. 
Group F (Latex patch): (Control group) 
Fig 15. Clinical picture of group F shows normal looking skin. 
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Group G {Latex protein iniectionllatex paint): (Positive control group) 
Fig 16. Normal looking clinical picture of group G at protein paint site. Note: skin was 
slightly abraded. 
Macroscopic Examination: 
Gross examination of all subcutaneous specimens was conducted 16 days after 
placing the implant material. The examination of H & E stained slides with a light 
microscope showed that the experimental materials were implanted in the fascial layers 
between the superficial and deep muscles of the back. 
In most specimens, a clear, fibrous film formed over the implanted material. All 
specimens showed signs of inflammation localized next to implanted material. The 
subcutaneous specimen of the injected protein showed inflammation at the injection site. 
The inflammatory reactions have been graded as mild and moderate. 
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Fig 17. A slide showing the difference between mild (right) and moderate 
inflammation (x200) 
Gross examination of all skin-patch-site specimens was performed 2 days after 
placing the patch. The examination showed normal histology (groups A➔ F) with intact 
epidermis and slightly abraded skin surface. The epidermis and dermis were of normal 
thickness with distinct epidermal and dermal ridges. The epidermis consists mainly of 
stratified squamous epithelium, and had scattered Langerhans cells, Merkel cells, and 
melanocytes. The dermis, which supports the epidermis and binds to the subcutaneous 
tissue (hypodermis, is composed of connective tissue containing fibroblasts, mast cells 
and macrophages. 
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Group A (Latex implant/gutta-percha patch): 
Subcutaneous tissue: This tissue was examined 16 days after placing the latex 
implant. The specimen showed traces of latex. The inflammatory reaction was moderate 
with a fibrous capsule of narrow thickness surrounding the latex implant material. The 
cell infiltration consisted of macrophages, lymphocytes, polymorphonuclear leukocytes 
and plasma cells mainly localized closer to the implant material. The specimen also 
included erythrocytes, connective tissue fibers tom from the implanting procedures and 
hair particles. 
In areas of milder inflammation, occasional macrophages and foreign body giant 
cells were spotted. A total of eight (8) slides of subcutaneous tissue stained with H&E 
were examined in this group. 
Fig 18. Group A (H&E) stained subcutaneous tissue showing implanted latex (L) and 
fibrous capsule (arrows) (x40) 
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Fig 19. Group A subcutaneous tissue showing macrophages (arrows) and latex (L) (x200) 
Fig 20. Group A subcutaneous section showing multinucleated giant cells (arrow) and 
macrophages (x400) 
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Fig 21. Group A subcutaneous tissue showing multinucleated giant cells (arrows) (x400) 
Fig 22. Group A subcutaneous section showing polymorphnuclear leukocytes -PMNs 
(arrows) and latex (L) (x200) 
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Fig 23. Group A subcutaneous tissue showing PMNs (arrows) and latex (L) (x400) 
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Skin patch specimen: The site was examined 2 days after placing the gutta-
percha patch. The examination shows a normal histological picture of skin. Eight (8) 
slides of H&E stained skin patches of group A were examined. 
Fig 24. Group A (H&E) stained skin patch section showing normal thickness and 
structure of dermis (D) and epidermis (E) (xlOO) 
Fig 25. Group A skin patch section showing normal epidermis (E) and dermis (D) (x200) 
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Group B Oatex implant/latex patch): 
Reactions were similar to that of Group A (latex implant/gutta-percha patch) in 
both the subcutaneous and the skin specimen. Six ( 6) H&E subcutaneous stained tissue 
were examined 16 days after placing the latex implant, and five ( 5) H&E stained skin 
tissue slides were examined 2 days after placing the latex patch. 
Fig 26. Group B (H&E) subcutaneous section showing latex (L) and a fibrous capsules 
(arrows) surrounding the implanted latex (x20) 
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Fig 27. Group B subcutaneous section showing macrophages (x200) 
Fig 28. Group B subcutaneous section showing macrophages (arrows) (x400) 
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Fig 29. Group B H&E stained skin patch section showing normal skin histology (xlO0) 
Fig 30. Group B skin patch section showing normal skin histology (x200) 
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Group C {gutta-percha implant/gutta-percha patch): 
Subcutaneous tissue: The tissue was examined 16 days after placing the gutta-
percha implant. The specimen shows traces of gutta-percha. The tissue bordering the 
gutta-percha showed a dense band of inflammatory cells of moderate intensity. There was 
an infiltrate of polymorphonuclear leukocytes, macrophages, lymphocytes, and plasma 
cells. The specimen also included erythrocytes, connective tissue fibers tom from the 
implanting procedures and hair particles. 
In milder areas of inflammation occasional macrophages and foreign body giant 
cells were spotted. A total of six ( 6) H&E stained subcutaneous tissue slides . were 
examined in this category. 
Fig 31. Group C (H&E) stained subcutaneous section showing gutta-percha (thick arrow) 
and a fibrous capsule (thin arrow) surrounding the implanted gutta-percha (x20). 
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Fig 32. Group C subcutaneous section showing gutta-percha (thin arrow) and 
PMNs (thick arrow) (x40). 
Fig33. Group C subcutaneous section showing macrophages and multinucleated 
giant cells (arrow) (x200). 
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Fig 34. Group C subcutaneous section showing macrophages (arrows) (x400). 
Skin patch specimen: The site shows a normal histological picture of skin. Skin tissue 
was examined 2 days after placing the gutta-percha patch. Six ( 6) slides of H&E stained 
skin patches of group C were examined. 
Fig.35. Group C skin patch section showing normal skin histology (xlOO). 
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Group D (gutta-percha implant/latex patch): 
Reactions were similar to that of Group C (gutta-percha implant/gutta-percha 
patch) in both the subcutaneous and the skin specimen. Eight (8) H&E stained 
subcutaneous tissue samples were examined 16 days after placing the gutta-percha 
implant. Eight (8) H&E stained skin specimens were examined 2 days after placing the 
latex patch. 
Fig 36. Group D (H&E) stained subcutaneous section showing gutta-percha ( arrow) and a 
fibrous capsule surrounding the implanted gutta-percha (x40) 
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Fig 37. Group D subcutaneous section showing gutta-percha (dotted arrow), macrophages 
(thin arrow) and multinucleated giant cells (thick arrow) (x200) 
Fig 38. Group D subcutaneous section showing gutta-percha (dotted arrow), macrophages 
(thick arrows) and multinucleated giant cells (thin arrow) (x400) 
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Fig 39. Group D H&E stained skin patch section showing normal skin histology (xlOO) 
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Groups E (no implant/gutta-percha patch): 
A total of six ( 6) H&E stained skin slides were examined 2 days after placing the patch. 
Fig 40. Group E skin patch section showing normal skin histology (x200) 
Group F (no implant/latex patch): 
A total of six ( 6) H&E stained skin slides were examined 2 days after placing the patch. 
Fig 41. Group F skin patch section showing normal skin histology (xl 00) 
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Group G (injected latex proteinAatex protein paint): 
Two (2) animals were assigned to this group, animal 1 (blue) and animal 2 (red). 
ANIMAL 1 (Blue): 
Subcutaneous (injected): Tissue was examined 16 days after injecting the latex protein. 
The injection site showed mild inflammation. A total of two (2) slides stained with H&E 
were examined. 
,,, 
Fig 42. Group G (blue) (H&E) stained subcutaneous injection site showing area of 
fibrous tissue infiltrated with inflammatory cells (x20). 
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Fig 43. Group G (blue) subcutaneous injection site (xlOO). 
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Skin paint area specimen: Two (2) slides of stained tissue were examined 2 days after 
placing the protein paint. The site shows a mild infiltration of inflammatory cells in the 
dermis (D). The epidermis (E) is intact and skin surface is slightly abraded. 
Fig 44. Group G (blue) skin patch section showing inflammatory cells (arrows) in dermis 
(D). Epidermis is intact (E). Protein (P) paint residue is seen attached to the abraded skin 
surface (xl00). 
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ANIMAL 2 (Red): 
Subcutaneous (injected): Tissue was examined 16 days after injecting the latex protein. 
The injection site showed mild inflammation. A total of Two (2) slides stained with H&E 
were examined. 
Fig 45. Group G (red) H&E stained subcutaneous injection site (x40). 
Fig 46. Group G (red) subcutaneous injection site (xl00) 
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Fig 47. Group G (red) subcutaneous injection site showing mild inflammation (left) 
(x200) and (right) showing macrophages (arrows) (x400). 
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Skin paint area specimen: Two (2) slides of skin tissue were examined 2 days after 
placing the protein paint. The site showed a mild infiltration of inflammatory cells in the 
dermis (D). The epidermis (E) is intact and skin surface is slightly abraded. 
Fig 48. Group G (red) skin patch section showing inflammatory cells (arrows) in dermis 
(D). Epidermis is intact (E) and skin surface is slightly abraded (xlOO). 
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Western blot assay results for groups A, B, C, and D: 
Using the Western Blot Assay, each serum was tested against ammoniated latex 
(AL) and non-ammoniated latex (NAL) proteins run in side-by-side wells. No reactivity 
was detected. Only one sample representing each experiment group (A, B, C and D-
excluding the control groups E and F) was picked for the Western Blot Assay. The 
samples picked were based on evidence of some histological changes. Blood samples 
tested were those drawn prior to the experiment [bl 1] and as the final blood draw [bl 5]. 
1 2 3 4 5 6 7 8 9 10 1 Marker 
2 AL l00µg 
313a 
3 NAL 20 µg 
4 AL l00µg 
313c 
5 NAL 20µg 
6 AL lO0µg 
316a 
7 NAL 20µg 
8 AL l00µg 
316c 
9 NAL 20µg 
10 -
Fig 49. Western blot results for groups A and B 
Ammoniated latex protein (AL) Non-ammoniated latex protein (NAL) 
a=[bl 1] blood draw before the experiment (Day 1) c=[bl 5] 2 days after painting latex protein (Day 16) 
Group A {latex/gutta-percha)(313a,c]: 
Wells 2 (AL) and 3 (NAL) contained blood drawn before the experiment. (Day 1) 
Wells 4(AL) and 5 (NAL) held blood drawn 2 days after placing the latex patch. (Day 
16) 
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Group B {latex/latex)[316a,c]: 
Wells 6(AL) and 7 (NAL) used blood drawn before the experiment. (Day 1) 
Wells 8(AL) and 9(NAL) tested blood drawn 2 days after placing the gutta-percha patch. 
(Day 16) 
1 2 3 4 5 6 7 8 9 IO 1 Marker 
I 
2 AL lO0µg 
319a 
I 
3 NAL 20µg 
4 AL l00µg 
I 
319c 
5 NAL 20µg 
6 AL l00µg 
322a 
7 NAL 20µg 
8 AL l00µg 
322c 
9 NAL 20µg 
10 -
Fig 50. Western blot results for groups C and D 
Group C {gutta-percha/ gutta-percha)[319a,c]: 
Wells 2 (AL) and 3 (NAL) held blood drawn before the experiment. (Day 1) 
Wells 4(AL) and 5 (NAL) used blood drawn 2days after placing the gutta-percha patch. 
(Day 16) 
Group D {gutta-percha/latex)[322a,c]: 
Wells 6(AL) and 7 (NAL) tested blood drawn before the experiment. (Day 1) 
Wells 8(AL) and 9(NAL) examined blood drawn 2 days after placing the latex patch. 
(Day 16) 
93 
Western blot assay results for ANIMAL 1 (Blue): 
2 3 4 5 6 7 8 9 IO 
1 Marker 
2 AL 
3 NAL 
4 AL 
- I 
j 5 NAL 
I 6 AN 
7 NAL 
8 AL 
9 NAL 
'lie_,::_ A3 
,{. Al. 4-1 10 -- ~ 
Fig 51. Western blot results for groups G ( animal I -blue) 
Al=blood draw before the experiment (Day 1) [bl 1) 
A2= 14 days after injection the latex protein (Day 14) [bl 2) 
A3= 2-3 days after painting latex protein (Day 16) [bl 5) 
No 1° 
Blue A3 
BlueA2 
Blue Al 
The blot for group G animal J(blue) sera showed that Al serum has no reactivity. 
A3 sera appear stronger than A2, but there does not appear to be any new bands showing 
up. The strongest band that appears in both AL and NAL (non-ammoniated latex) in both 
A2 and A3 is the 43-kDa (Hev b 7 band). 
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W estem blot assay results for ANIMAL 2(Red): 
2 3 4 5 6 7 8 9 10 1 Marker 
2 AL 
-= · 3 NAL 
4 AL 
-
5 NAL 
6 AL 
7 NAL 
8 AL 
9 NAL 
Rtd ii) ~ul. A3 , llUil A.l l\ttl It\ 10 -
Fig 52. Western blot results for groups G ( animal 2-red) 
Al=blood draw before the experiment (Day 1) [bl 1] 
A2= 14 days after injection the latex protein (Day 14) [bl 2) 
RedA3 
RedA3 
RedA2 
Red Al 
A3= 2-3 days after painting latex protein (note: 2 gel lanes for A3) (Day 16) [bl S] 
Similar to animal 1 (blue), the blot for group G animal 2 (red) sera showed 
distinct bands demonstrated for both the AL and NAL protein in the A3 sera. Al sera 
showed no reactivity. A2 sera demonstrated some distinct bands along with diffuse 
staining in the gel lane. These same bands showed in A3, but were stronger than A2. The 
strongest band that appears in both AL and NAL was mainly at 43-kDa (Hev b 7 band). 
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Summary of results: 
Group Clinical Histological picture Western Blot 
picture Assay 
Subcutaneous tissue Skin patch site tissue bl 1 bl 2 bl 5 
A (latex /gutta-percha) normal Moderate inflammatory reaction normal N/R NIA N/R 
B (latex /latex) normal Moderate inflammatory reaction normal N/R NIA N/R 
C (gutta-percha /gutta-percha) normal Moderate inflammatory reaction normal N/R NIA N/R 
D (gutta-percha /latex) normal Moderate inflammatory reaction normal N/R NIA N/R 
E (none /gutta-percha) normal NIA normal NIA NIA N/R 
F (none /latex) normal NIA normal NIA NIA N/R 
G (latex protein/protein paint) normal Mild inflammatory reaction normal N/R R R 
N /R: No Reaction R: reaction NIA: Non Applicable 
bl 1: 1st blood draw before placing implants and protein injection (Day 1) 
bl 5: final blood draw before euthanasia of animal (Day 16) 
bl 2: 2nd blood draw after placin g the implant and protein injection (Day 14) 
Table 4. Summary of results 
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DISCUSSION 
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DISCUSSION 
Allergic responses to NRL products include contact dermatitis, asthmatic 
bronchospasms, and life-threatening anaphylactic shock (Slater, 1994; Landwehr & 
Boguniewicz 1996). Greater than 80% of the allergic responses to NRL products are due 
to Type IV delayed-type hypersensitivity (DTH) directed toward chemical processing 
aids used during product manufacture (Conde-Salazar et al., 1993). IgE-mediated Type I 
reactions to latex are potentially more severe and have been shown to be directed towards 
residual NRL proteins which remain on products following the manufacturing process 
(Posch et al., 1998; Jaeger et al., 1992; Alenius et al., 1991 ). 
Composition of NRL and gutta-percha: 
NRL and gutta-percha are similar in background and chemical composition. NR is 
derived from the latex of the rubber tree Hevea brasiliensis. Gutta-percha is derived from 
Paliquium gutta that is from the same botanical family as the rubber tree, and there lies 
the potential of cross-reactivity. Due to their close molecular structures, gutta-percha and 
NRL have a number of similarities in their physical properties. Gutta-percha is a 
stereoisomer of isoprene and so is NRL. They both have the same formula (C5H8) 
(Marciano & Michailesco, 1989; Bunn, 1942) and their polymers are made up of the 
same repeating unit. The difference in their mechanical behavior is related to their 
different forms as the orientation of the repeating polymer units in the molecular chain 
changes (cis-, and trans-I, 4-isopeme) (Marciano & Michailesco, 1989; Goodman, 
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1974). Gutta-percha is a partially crystalline polymer as opposed to the amorphous form 
ofNRL. 
CH3 
I 
CH2==C-CH==CH2 
ISOPRENE FORMULA (C5H8) 
CH3 CHr~ CH3 
\ I \ I 
C==C C==C 
I \ I \ 
CH2-CH2 H ~~~H2C 
H CH3 H 
\ I 
C==C 
I \ 
CH2-CH2 CHr ~ 
Gutta-percha (trans-ionomer) Natural Rubber (cis-isomer) 
Modem commercially prepared gutta-percha obturation cones contain only 
approximately 20% of the natural product. Their similarity in chemical make-up and 
background could produce cross-reactivity, but the difference in the manufacturing 
process of NRL and gutta-percha may keep that cross-reactivity to a minimum. Gutta-
percha is generally viewed as a nontoxic obturating material. Although more than 100 
years have passed since its introduction, gutta-percha is still considered the material of 
choice for filling root canals. 
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Materials used: 
The selection of the materials used in this study (gutta-percha and latex) was 
based on their widespread use. The gutta-percha was implanted in the fascia! layers 
between the superficial and deep muscles of the back of the guinea pigs. This approach 
mimics the way gutta-percha is used clinically during endodontic procedure. Once it gets 
to the apical foramen or beyond, it is in contact with the periodontal tissue surrounding 
the root apex. 
Latex glove pieces were implanted in the same manner as gutta-percha. Although 
latex pieces have not been implanted subcutaneously in previous studies, Spina Bifida 
(SB) patients are exposed to latex subcutaneously. It was implanted in this study to 
uniformly mirror the way both latex and gutta-percha implants are handled. It was also 
implanted to determine if this route of exposure to latex pieces would cause any 
allerginicty and sensitize the guinea pigs. The concentrations of latex proteins chosen in 
this study were consistent with potential human exposure levels. Latex examination 
gloves have been shown to contain 0.2-400µ,g proteins per glove (Zehr & Beezhold, 
1995), and approximately 75% of powdered gloves evaluated had greater than l00µg of 
latex protein per gram of glove (Swanson et al., 1994). 
Protein from NAL was used as the test material due to its improved protein 
profiles as compared to AL (ammoniated latex) (Woolhiser et al., 2000). 
Guinea pigs were selected because of the relative ease with which they can be 
sensitized to protein antigens and their capability of inducing the production of antibodies 
that cause de1mal and systemic reactions similar to those of humans. (Aamir et al., 1996). 
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Clinical findings: 
All clinical findings from the skin tissue of all groups (A ➔G) were normal, 
showing no apparent indication of any inflammatory or allergic reaction to any of the 
patch-tested materials (latex and gutta-percha). The only redness noticed at the patch site 
corresponded to the site of the sutures that were used to attach the patches. 
Abrading the skin removed the stratum comeum layer of skin. This layer is 
considered to be the major barrier between topically applied antigens and the skin 
immune system. Many latex sensitive individuals, such as health care workers (HCW) 
suffer from hand dermatitis caused by various factors including hand washing (Larson et 
al., 1986; Lammintausta & Kalmino, 1981) and extensive glove usage (Turjanmaa, 
1994). Dermatitis compromises the stratum comeum layer. Thus, an abraded- skin model 
mimics the skin condition of latex sensitive individuals. 
Histological and immunological effects oflatex and gutta-percha implants: 
Histological changes: 
Histologically, the latex implant groups (A&B /latex implant) showed moderate 
chronic inflammatory response with macrophage cell infiltration in the subcutaneous 
tissue surrounding the latex implant. The appearance of scattered multinucleated giant 
cells suggests a foreign body reaction showing phagocytic response. This may be a 
response to irritants ( chemicals and additives to latex gloves during manufacturing 
process). 
Similarly, histological findings of the gutta-percha implant groups (C&D /gutta-
percha implant) showed moderate chronic inflammatory response with macrophage cell 
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infiltration around the gutta-percha implant. Also, scattered multinucleated giant cells 
suggest a foreign body reaction showing phagocytic response. Gutta-percha is the least 
irritating, non-toxic root canal filling material (Spangberg, 1969; Wolfson & Seltzer, 
1975). The histological results of subcutaneous tissue reaction to gutta-percha implants in 
this study are consistent with those made by Holland et al., (1978), and Leonardo et al., 
(1990) in the first 7-14 days (their experiment tested difference in tissue reaction 
extending to 120 days). Some of this inflammation may be due to incising the skin to 
place the implants. 
The normal clinical and histological picture was expected for groups E and F 
(negative control groups). Groups E (gutta-percha patch) and F (latex patch) received no 
implants. They showed no reaction and their skin looked normal. The histological picture 
confirmed the clinical evaluation. There were no changes in the skin histology. This 
shows that latex and gutta-percha may cause minor temporary irritation but not an 
allergic reaction in individuals who do not have Type I or Type IV allergy to NRL. 
Since there was no evidence for sensitization in animal groups A ➔ D according 
to the immunological test, their reaction to the skin patches (latex or gutta-percha) was 
deemed normal and similar to the negative control groups E and F. 
For the positive control group G (latex injection/latex paint), the histology of the 
subcutaneous injection site showed a mild inflammatory reaction with infiltration of 
chronic inflammatory cells , mainly macrophages. The inflammation could be due to the 
introduction of protein into the tissue. Whether or not this reaction was going to subside 
over a period of time as was the case with gutta-percha implants is unknown due to the 
time frame of this study. However, an immunological change took place in this group, 
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and could very well start a cascade of inflammatory reactions. Histological examination 
of the skin in the area of the latex paint showed infiltration of inflammatory cells in the 
dermis layer just underneath the junction of the dermis and epidermis layers. Since there 
were no microvesicles in the epidermis, thus it is not a type IV allergy. It is contact 
irritation and foreign bogy reaction. This is consistent with studies concluding that type 
IV allergy is a reaction to the chemicals added to latex gloves and not the latex proteins 
(Themido & Brandao, 1984; Conde-Salazar et al., 1993). 
Immunological changes: 
W estem blot for groups A➔ D showed no reactivity. While group G showed 
evidence of antibody production to anti-guinea pig IgG, anti-guinea pig IgE reagent is 
not available, and presence of antibodies of this isotype could not be determined. The 
major reaginic antibody for the guinea pig is IgG 1, in contrast to IgE for humans (Aamir 
et al., 1996). The strongest reactivity that appeared in both AL and NAL was expressed 
with a thickened band mainly at the 43-kDa marker. This corresponds to Hevb 7 protein. 
From studies, Wagner et al. (2001) concluded that Rubber Elongation Factor [REF] Hevb 
1(14-KDa), Hevb 3(22-27 KDa) and Hevb 7(43 KDa) are recognized more frequently by 
IgE from SB patients. This is in agreement with the route of exposure since SB patients 
mainly are the group that gets exposed to latex subcutaneously in conjunction with other 
routes. The guinea pigs in this group (G) were exposed to latex by subcutaneous protein 
injection. 
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Allerginicity of latex and gutta-percha: 
Routes of exposure to latex could include direct contact with skin, oral mucosa or 
inhalation ( aero allergen). However, routes of exposure to gutta-percha could be dermal or 
oral mucosa contact as well as apical contact at root tip. In patients with Type IV allergy 
to one or more of chemicals involved with manufacturing latex or gutta-percha , oral 
mucosa and skin may show signs of itching, swelling, redness and burning. Grade & 
Martens (1989) reported allergic reaction after exposure to eugenol. It is usually a 
delayed reaction but some Type IV allergic reactions have an acute and immediate onset. 
It should not be confused with Type I hypersensitivity or with dermal irritation that is 
similar to Type IV hypersensitivity (Gazelius et al. 1986). If the patient is not allergic, 
the chemicals in gloves, disinfectants and gutta-percha solvents can be a source of 
irritation causing inflammatory reaction that decreases in intensity with time (Holland et 
al., 1978; Leonardo et al., 1990). From our study, it does not appear though that there is 
allerginicty to gutta-percha. 
Apparently, implanting latex subcutaneously is not considered as a route of 
exposure to get sensitized to latex in healthy individuals. Meanwhile, the positive control 
group injected subcutaneously with latex protein showed reactivity and was sensitized to 
latex consistent with the findings of the route of sensitization investigated by Woolhiser 
et al. (2000). Although SB patients are exposed to latex subcutaneously, it is not 
confirmed that this was the route of exposure that caused their latex sensitivity. They 
have increased incidence because of their frequent exposure to latex products from birth. 
Up to 70% of SB patients have been diagnosed with IgE mediated latex allergy (Kelly et 
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al., 1994; Cremer et al., 1998). Chen et al. (1997) and Porri et al. (1997) support the 
possibility of mucosa! or subcutaneous sensitization in their studies. They linked that to a 
positive correlation between the number of surgical procedures and latex allergy 
prevalence within these patient populations, but the latex implant groups (A&B) did not 
show any allerginicty to latex. In patients with SB, physiological fluids from surgical 
patients who come in contact with NRL products may elute additional latex proteins 
allowing for exposure to a unique set of proteins. The fact that SB patients already have 
IgE to NRL may contribute to this eluting of proteins. Implanting latex may affect the 
amount of extractable protein in a patient who does not have IgE as in SB patients. 
In animal experiments, the materials have been applied to normal tissue whereas 
in clinical practice gutta-percha is mostly applied to inflamed and/or infected tissue of the 
periapical area. These conditions often exist prior to root canal treatment. Weather this 
affects the intensity or the potentiality of allergic reaction or not is unknown. The fact is 
also true in first time exposure to latex. Thus, exposure to allergens over a period of time 
is another factor that may eventually lead to an allergic reaction. 
On the other hand, the adjuvant(s) used could have contributed to expressing the 
allergic reaction. Although Freund's Complete Adjuvant (FCA) has been used for many 
years to enhance immunologic responses to antigens and has been a very effective 
adjuvant for production of antibodies, there have been problems and hazards associated 
with its use. TiterMax adjuvant was developed it in 1991 specifically as a replacement for 
FCA (Hunter et al., 1991). When compared to FCA, Titer Max can be used in smaller 
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quantities, which minimizes the inflammatory reaction at the site used (Bennett et al., 
1992). However, it might have not enhanced any immunological response in our study 
with the latex implant. This may be due to the form in which the latex was used (pieces 
of latex glove). Alum adjuvant was used with the latex protein aliquots in group G. A 
positive reaction was induced in this group. Whether this was an effective factor in 
inducing the allergic reaction or it affected the intensity is unknown. 
Cross-reaction between gutta-percha and latex: 
Initially, from the clinical examination and lack of allergic reaction in group A 
(Latex implant/gutta-percha patch), it can be concluded that there was no cross-reaction 
between gutta-percha and NRL. Meanwhile, as the Western blot showed no formation of 
IgE or antibodies to NRL in group A, it is obvious that this group was not sensitized to 
latex. However, based on the results from other studies that were being conducted at the 
same time as this study was, it is still possible to assume that there is no cross-reactivity 
between gutta-percha and NRL. Studies by Hamann et al. (2002) and Costa et al. (2001) 
found that there was no detectable cross-reactivity between NRL and gutta-percha. 
Costa's study was done in vitro while Hamann' s study was partially done in vivo using 
skin prick test on patients with Type I NRL allergy, and analyzing gutta-percha samples 
by RAST, immunoblot inhibition, direct ELISA and ELISA inhibition. In their study, 
Hamann and his colleagues (2002) confirmed from the skin prick test that it is unlikely 
patients with Type I NRL will develop allergic reactions to commercial gutta-percha . 
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Boxer et al. (1994) reported diffuse urticaria and swelling in a Type I NRL 
allergic individual during an endodontic procedure. Symptoms persisted after the 
procedure but apparently resolved when the gutta-percha was removed one month later. 
In 1986, Gazelius et al. recorded a case of long-term reaction to gutta-percha in an 
individual with Type IV allergy to rubber chemicals. However, in both cases, their 
conclusions were based on assumptions that the similar botanical background between 
gutta-percha and NRL implied cross-reactivity. It was also assumed that the endodontic 
gutta-percha points contain significant amounts of gutta-percha protein , and that other 
endodontic materials used in the procedures were not allergic. These reports, however, 
have not proven cross-reactivity between Hevea latex and gutta-percha. It is known now 
that patients with NRL allergy can have concomitant allergies to certain foods (Lavaud et 
al., 1992; Makinen-Kiljunen, 1994), plants (Axelsson, Johansson & Zetterstrom, 1987; 
' Brehler et al., 1998), pollens and chemicals (Wrangsjo et al., 1994; Turjanmaa, 
1994;Themido & Brandao, 1984). Endodontic chemicals that are potential allergens 
include eugenol, disinfectants and epoxy resins (Grade & Martens, 1989). Thus the 
allergic reaction thought to be from gutta-percha could in fact be allergy to any other 
compound used during the endodontic procedure. Other clinicians (Knowles & Kelier) 
have described successful root canal placement of gutta-percha in patients with Type I 
NRL allergy (Kleier & Shibilski, 1999; Knowles et al., 1998). Their case report 
demonstrates that there is no automatic cross-reactivity with gutta-percha in patients who 
are allergic to latex. The divergent clinical outcomes could be due to variations in 
patients' immunological sensitivity or chemical allergens. 
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Hamann et al. (2002) explained that gutta-percha had no potential to elicit a 
response in people with Type I hypersensitivity. Some allergenic reaction though was 
detected between raw gutta-percha and raw NRL (Hamann et al., 2002) using Direct 
ELISA and ELISA inhibition tests. Costa and his colleagues (2001) did not detect any 
cross-reactivity between raw or clinically used gutta-percha and NRL using RAST 
inhibition test. However the cross-reactivity between raw gutta-percha and NRL is not 
likely to have clinical relevance. The procedures used to manufacture commercial gutta-
percha differ widely from those used in production of latex. The process of 
manufacturing of gutta-percha endodontic points involves purification with harsh organic 
solvents and a combination of heat and gasoline extracts. This may result in denaturing of 
any plant protein in the gutta-percha (Costa et al., 2001). The absence of extractable 
protein from commercial gutta-percha indicates that their use in individuals who have IgE 
NRL allergy represents a minimal risk, as they will not cross-react with Hevea latex and 
will not induce an allergic reaction. 
Raw gutta-balata releases proteins that cross-react with Hevea latex (Costa et al., 
2001). Occasionally when gutta-percha is in short supply, manufacturers add some gutta-
balata or synthetic trans-polyisoprene to gutta-percha cones. The synthetic version would 
not be expected to contain any Hevea latex cross-reactive proteins. However, when gutta-
balata is used, the manufacturers do not disclose its presence or percentage. 
Manufacturers of gutta-percha products should be encouraged to eliminate the addition of 
any gutta-balata in their formulation, although its proteins may also be denatured as with 
raw gutta-percha while being processed to the finished commercial gutta-percha 
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endodontic points. The studies by both Hamann et al. (2002) and Costa et al. (2001) were 
not able to demonstrate any cross-reaction between commercial gutta-percha and purified 
NRL allergen. 
Clinical Implications: 
. Gutta-percha has been the material of choice for root canal obturation. It is the 
least allergenic material available when retained within the canal system, demonstrating 
minimal toxicity and tissue irritability, even when accidentally overextended into 
periradicular tissue. This study and others concluded that gutta-percha (raw and 
commercial) did not cause sensitization to latex, and that there was no cross-reactivity 
detected between gutta-percha and NRL. However, other studies concluded that gutta-
balata releases proteins that cross-react with NRL. If gutta-percha is to be used in patients 
with latex sensitivity, the dentist should confirm with the manufacturer that the product to 
be used does not have gutta-balata. The dentist should be careful not to fill beyond the 
root apex during endodontic obturation to avoid any possibility of an allergic reaction via 
blood circulation. Patients with latex-allergies should be informed of the obturation 
process and the materials used. Additionally, other treatment options and obturation 
materials should be discussed. These patients often have a strong and lengthy history of 
allergies and may react to one or more of the dental chemicals used in root canal 
obturation. The synthetic version of gutta-percha would not be expected to contain any 
Hevea latex cross-reactive proteins. 
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Management of Type I NRL sensitive patients: 
Guidelines for the care for Type I NRL allergic patients recommended that they 
should be treated in an environment with minimal latex presence. Several precautions 
should be considered that could reduce the risk of an allergic reaction occurring in the 
dental office. Dentists must evaluate patients' medical histories carefully for documented 
allergies including food allergies. Staff and patients should be educated about latex 
allergies , and it should be recognized that SB patients and HCW are at higher risk. When 
treating pati ents with Type I NRL allergy, the patient should be given the first 
appointment in the day with no latex in the room. Non-latex gloves, rubber dam and 
materials should be used. Attention should be paid to potential reactions to other dental 
chemicals, rubber anesthetic cartridge stoppers (DNR), anesthetics and disinfectant 
(Wilson et al., 2000). 
Should the patient develop a latex allergy reaction during treatment , vital signs 
must be monitored. Assisted ventilation may become necessary. If blood pressure drops, 
0.3-0.5ml Of 1: 100 aqueous epinephrine IM is applied, and if necessary , 50 mg 
diphenhydramine IV, IM or PO. Localized cutaneous reactions such as wheal-type , 
respond to antihistamine such as diphenhydramine (25-50mg), hydroxyzine (10-50), or 
terfenadine (60mg). For surgical procedures, a recommended preoperative regimen for 
patients with latex allergies is diphenhydramine lmg/Kg every 6 hours 24 hours before 
surgery (Landwehr & Boguniewicz, 1996). 
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CONCLUSION 
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CONCLUSION 
This in vivo study lead to the following conclusions: 
1. Injection of latex protein sensitized guinea pigs to latex in 14 days, while implanted 
latex glove pieces had no allergenic capability and did not show any reaction to the 
Western blot. Thus, the route of exposure to latex might affect its allergenic property. 
2. Implanted latex glove pieces cause mild inflammation in surrounding subcutaneous 
tissue. 
3. Although implanted gutta-percha causes moderate inflammation to surrounding 
tissue, it did not sensitize guinea pigs to latex, as it did not show any reaction to the 
Western blot. 
4. There was no apparent cross-reaction between gutta-percha and latex in this animal 
study. 
112 
FUTURE STUDIES 
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FUTURE STUDIES 
This study focused on gutta-percha as a potential cross-reactive agent to NRL. 
Future studies may extend the time frame of this study and expand testing to include 
other materials and chemicals used during endodontic obturations, such as sealers to 
determine if they have any allergenic effect in latex sensitive patients. 
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